AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPhenomena and ProcessesInformation ScienceHealth Care
Multiple MyelomaMyeloma ProteinsBoronic AcidsPyrazinesThalidomidePlasma CellsMelphalanParaproteinemiasMonoclonal Gammopathy of Undetermined SignificanceLeukemia, Plasma CellPlasmacytomaDexamethasoneTransplantation, AutologousSyndecan-1Bone MarrowAntineoplastic AgentsCell Line, TumorBence Jones ProteinParaproteinsImmunoglobulin Light ChainsAntineoplastic Combined Chemotherapy ProtocolsProteasome InhibitorsHematopoietic Stem Cell TransplantationOsteolysisBone DiseasesInterleukin-6Waldenstrom MacroglobulinemiaApoptosisChromosomes, Human, Pair 14Tumor Cells, CulturedMice, SCIDBone Marrow CellsImmunoglobulin kappa-ChainsDiphosphonatesVincristineSyndecansPrednisonePrognosisMaintenance ChemotherapyTreatment OutcomeImmunoglobulin lambda-ChainsAntineoplastic Agents, AlkylatingRemission InductionStem Cell TransplantationDrug Resistance, NeoplasmTranslocation, GeneticDoxorubicinGene Expression Regulation, NeoplasticCombined Modality TherapyRecurrenceSurvival AnalysisSurvival RateCyclophosphamideProtease InhibitorsStromal CellsChromosomes, Human, Pair 13Cell ProliferationHypergammaglobulinemiabeta 2-MicroglobulinAmyloidosisDisease-Free SurvivalFlow CytometryBone Marrow ExaminationSalvage TherapyDisease ProgressionCell SurvivalReceptors, Interleukin-6Chromosomes, Human, Pair 4Immunologic FactorsReceptor, Fibroblast Growth Factor, Type 3In Situ Hybridization, FluorescenceImmunoglobulin DNeoplasm ProteinsNeoplasms, Plasma CellDrug SynergismChromosome AberrationsOsteoclastsAntibodies, MonoclonalXenograft Model Antitumor AssaysImmunoglobulinsHematopoietic Stem Cell MobilizationPeripheral Blood Stem Cell TransplantationTransplantation ConditioningSignal TransductionAngiogenesis InhibitorsLymphomaImmunoglobulin AHematologic NeoplasmsB-LymphocytesOsteonecrosisInduction ChemotherapyRetrospective StudiesTime FactorsCell DivisionOxides
Multiple Myeloma: A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.Myeloma Proteins: Abnormal immunoglobulins characteristic of MULTIPLE MYELOMA.Boronic Acids: Inorganic or organic compounds that contain the basic structure RB(OH)2.PyrazinesThalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.Plasma Cells: Specialized forms of antibody-producing B-LYMPHOCYTES. They synthesize and secrete immunoglobulin. They are found only in lymphoid organs and at sites of immune responses and normally do not circulate in the blood or lymph. (Rosen et al., Dictionary of Immunology, 1989, p169 & Abbas et al., Cellular and Molecular Immunology, 2d ed, p20)Melphalan: An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - MELPHALAN, the racemic mixture - MERPHALAN, and the dextro isomer - MEDPHALAN; toxic to bone marrow, but little vesicant action; potential carcinogen.Paraproteinemias: A group of related diseases characterized by an unbalanced or disproportionate proliferation of immunoglobulin-producing cells, usually from a single clone. These cells frequently secrete a structurally homogeneous immunoglobulin (M-component) and/or an abnormal immunoglobulin.Monoclonal Gammopathy of Undetermined Significance: Conditions characterized by the presence of M protein (Monoclonal protein) in serum or urine without clinical manifestations of plasma cell dyscrasia.Leukemia, Plasma Cell: A rare, aggressive variant of MULTIPLE MYELOMA characterized by the circulation of excessive PLASMA CELLS in the peripheral blood. It can be a primary manifestation of multiple myeloma or develop as a terminal complication during the disease.Plasmacytoma: Any discrete, presumably solitary, mass of neoplastic PLASMA CELLS either in BONE MARROW or various extramedullary sites.Dexamethasone: An anti-inflammatory 9-fluoro-glucocorticoid.Transplantation, Autologous: Transplantation of an individual's own tissue from one site to another site.Syndecan-1: A syndecan that interacts with EXTRACELLULAR MATRIX PROTEINS and plays a role CELL PROLIFERATION and CELL MIGRATION.Bone Marrow: The soft tissue filling the cavities of bones. Bone marrow exists in two types, yellow and red. Yellow marrow is found in the large cavities of large bones and consists mostly of fat cells and a few primitive blood cells. Red marrow is a hematopoietic tissue and is the site of production of erythrocytes and granular leukocytes. Bone marrow is made up of a framework of connective tissue containing branching fibers with the frame being filled with marrow cells.Antineoplastic Agents: Substances that inhibit or prevent the proliferation of NEOPLASMS.Cell Line, Tumor: A cell line derived from cultured tumor cells.Bence Jones Protein: An abnormal protein with unusual thermosolubility characteristics that is found in the urine of patients with MULTIPLE MYELOMA.Paraproteins: Abnormal immunoglobulins synthesized by atypical cells of the MONONUCLEAR PHAGOCYTE SYSTEM. Paraproteins containing only light chains lead to Bence Jones paraproteinemia, while the presence of only atypical heavy chains leads to heavy chain disease. Most of the paraproteins show themselves as an M-component (monoclonal gammopathy) in electrophoresis. Diclonal and polyclonal paraproteins are much less frequently encountered.Immunoglobulin Light Chains: Polypeptide chains, consisting of 211 to 217 amino acid residues and having a molecular weight of approximately 22 kDa. There are two major types of light chains, kappa and lambda. Two Ig light chains and two Ig heavy chains (IMMUNOGLOBULIN HEAVY CHAINS) make one immunoglobulin molecule.Antineoplastic Combined Chemotherapy Protocols: The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.Proteasome Inhibitors: Compounds that inhibit the function or proteolytic action of the PROTEASOME.Hematopoietic Stem Cell Transplantation: Transfer of HEMATOPOIETIC STEM CELLS from BONE MARROW or BLOOD between individuals within the same species (TRANSPLANTATION, HOMOLOGOUS) or transfer within the same individual (TRANSPLANTATION, AUTOLOGOUS). Hematopoietic stem cell transplantation has been used as an alternative to BONE MARROW TRANSPLANTATION in the treatment of a variety of neoplasms.Osteolysis: Dissolution of bone that particularly involves the removal or loss of calcium.Bone Diseases: Diseases of BONES.Interleukin-6: A cytokine that stimulates the growth and differentiation of B-LYMPHOCYTES and is also a growth factor for HYBRIDOMAS and plasmacytomas. It is produced by many different cells including T-LYMPHOCYTES; MONOCYTES; and FIBROBLASTS.Waldenstrom Macroglobulinemia: A lymphoproliferative disorder characterized by pleomorphic B-LYMPHOCYTES including PLASMA CELLS, with increased levels of monoclonal serum IMMUNOGLOBULIN M. There is lymphoplasmacytic cells infiltration into bone marrow and often other tissues, also known as lymphoplasmacytic lymphoma. Clinical features include ANEMIA; HEMORRHAGES; and hyperviscosity.Apoptosis: One of the mechanisms by which CELL DEATH occurs (compare with NECROSIS and AUTOPHAGOCYTOSIS). Apoptosis is the mechanism responsible for the physiological deletion of cells and appears to be intrinsically programmed. It is characterized by distinctive morphologic changes in the nucleus and cytoplasm, chromatin cleavage at regularly spaced sites, and the endonucleolytic cleavage of genomic DNA; (DNA FRAGMENTATION); at internucleosomal sites. This mode of cell death serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth.Chromosomes, Human, Pair 14: A specific pair of GROUP D CHROMOSOMES of the human chromosome classification.Tumor Cells, Cultured: Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely.Mice, SCID: Mice homozygous for the mutant autosomal recessive gene "scid" which is located on the centromeric end of chromosome 16. These mice lack mature, functional lymphocytes and are thus highly susceptible to lethal opportunistic infections if not chronically treated with antibiotics. The lack of B- and T-cell immunity resembles severe combined immunodeficiency (SCID) syndrome in human infants. SCID mice are useful as animal models since they are receptive to implantation of a human immune system producing SCID-human (SCID-hu) hematochimeric mice.Bone Marrow Cells: Cells contained in the bone marrow including fat cells (see ADIPOCYTES); STROMAL CELLS; MEGAKARYOCYTES; and the immediate precursors of most blood cells.Immunoglobulin kappa-Chains: One of the types of light chains of the immunoglobulins with a molecular weight of approximately 22 kDa.Diphosphonates: Organic compounds which contain P-C-P bonds, where P stands for phosphonates or phosphonic acids. These compounds affect calcium metabolism. They inhibit ectopic calcification and slow down bone resorption and bone turnover. Technetium complexes of diphosphonates have been used successfully as bone scanning agents.Vincristine: An antitumor alkaloid isolated from VINCA ROSEA. (Merck, 11th ed.)Syndecans: A family of transmembrane glycoproteins that contain a short cytoplasmic domain, a single-span transmembrane domain, and an extracellular domain with heparin sulfate and CHONDROITIN SULFATE chains. Syndecans interact with a variety of heparin-binding INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS and may play a role in modulating cellular signaling during EMBRYONIC DEVELOPMENT, tumorigenesis, and angiogenesis.Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.Prognosis: A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations.Maintenance Chemotherapy: Treatment designed to help prevent a relapse of a disease following the successful primary treatments (INDUCTION CHEMOTHERAPY and CONSOLIDATION CHEMOTHERAPY) with a long-term low-dose drug therapy.Treatment Outcome: Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.Immunoglobulin lambda-Chains: One of the types of light chain subunits of the immunoglobulins with a molecular weight of approximately 22 kDa.Antineoplastic Agents, Alkylating: A class of drugs that differs from other alkylating agents used clinically in that they are monofunctional and thus unable to cross-link cellular macromolecules. Among their common properties are a requirement for metabolic activation to intermediates with antitumor efficacy and the presence in their chemical structures of N-methyl groups, that after metabolism, can covalently modify cellular DNA. The precise mechanisms by which each of these drugs acts to kill tumor cells are not completely understood. (From AMA, Drug Evaluations Annual, 1994, p2026)Remission Induction: Therapeutic act or process that initiates a response to a complete or partial remission level.Stem Cell Transplantation: The transfer of STEM CELLS from one individual to another within the same species (TRANSPLANTATION, HOMOLOGOUS) or between species (XENOTRANSPLANTATION), or transfer within the same individual (TRANSPLANTATION, AUTOLOGOUS). The source and location of the stem cells determines their potency or pluripotency to differentiate into various cell types.Drug Resistance, Neoplasm: Resistance or diminished response of a neoplasm to an antineoplastic agent in humans, animals, or cell or tissue cultures.Translocation, Genetic: A type of chromosome aberration characterized by CHROMOSOME BREAKAGE and transfer of the broken-off portion to another location, often to a different chromosome.Doxorubicin: Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN.Gene Expression Regulation, Neoplastic: Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in neoplastic tissue.Combined Modality Therapy: The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used.Recurrence: The return of a sign, symptom, or disease after a remission.Survival Analysis: A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function.Survival Rate: The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods.Cyclophosphamide: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.Protease Inhibitors: Compounds which inhibit or antagonize biosynthesis or actions of proteases (ENDOPEPTIDASES).Stromal Cells: Connective tissue cells of an organ found in the loose connective tissue. These are most often associated with the uterine mucosa and the ovary as well as the hematopoietic system and elsewhere.Chromosomes, Human, Pair 13: A specific pair of GROUP D CHROMOSOMES of the human chromosome classification.Cell Proliferation: All of the processes involved in increasing CELL NUMBER including CELL DIVISION.Hypergammaglobulinemia: An excess of GAMMA-GLOBULINS in the serum due to chronic infections or PARAPROTEINEMIAS.beta 2-Microglobulin: An 11-kDa protein associated with the outer membrane of many cells including lymphocytes. It is the small subunit of the MHC class I molecule. Association with beta 2-microglobulin is generally required for the transport of class I heavy chains from the endoplasmic reticulum to the cell surface. Beta 2-microglobulin is present in small amounts in serum, csf, and urine of normal people, and to a much greater degree in the urine and plasma of patients with tubular proteinemia, renal failure, or kidney transplants.Amyloidosis: A group of sporadic, familial and/or inherited, degenerative, and infectious disease processes, linked by the common theme of abnormal protein folding and deposition of AMYLOID. As the amyloid deposits enlarge they displace normal tissue structures, causing disruption of function. Various signs and symptoms depend on the location and size of the deposits.Disease-Free Survival: Period after successful treatment in which there is no appearance of the symptoms or effects of the disease.Flow Cytometry: Technique using an instrument system for making, processing, and displaying one or more measurements on individual cells obtained from a cell suspension. Cells are usually stained with one or more fluorescent dyes specific to cell components of interest, e.g., DNA, and fluorescence of each cell is measured as it rapidly transverses the excitation beam (laser or mercury arc lamp). Fluorescence provides a quantitative measure of various biochemical and biophysical properties of the cell, as well as a basis for cell sorting. Other measurable optical parameters include light absorption and light scattering, the latter being applicable to the measurement of cell size, shape, density, granularity, and stain uptake.Bone Marrow Examination: Removal of bone marrow and evaluation of its histologic picture.Salvage Therapy: A therapeutic approach, involving chemotherapy, radiation therapy, or surgery, after initial regimens have failed to lead to improvement in a patient's condition. Salvage therapy is most often used for neoplastic diseases.Disease Progression: The worsening of a disease over time. This concept is most often used for chronic and incurable diseases where the stage of the disease is an important determinant of therapy and prognosis.Cell Survival: The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability.Receptors, Interleukin-6: Cell surface receptors that are specific for INTERLEUKIN-6. They are present on T-LYMPHOCYTES, mitogen-activated B-LYMPHOCYTES, and peripheral MONOCYTES. The receptors are heterodimers of the INTERLEUKIN-6 RECEPTOR ALPHA SUBUNIT and the CYTOKINE RECEPTOR GP130.Chromosomes, Human, Pair 4: A specific pair of GROUP B CHROMOSOMES of the human chromosome classification.Immunologic Factors: Biologically active substances whose activities affect or play a role in the functioning of the immune system.Receptor, Fibroblast Growth Factor, Type 3: A fibroblast growth factor receptor that regulates CHONDROCYTE growth and CELL DIFFERENTIATION. Mutations in the gene for fibroblast growth factor receptor 3 have been associated with ACHONDROPLASIA; THANATOPHORIC DYSPLASIA and NEOPLASTIC CELL TRANSFORMATION.In Situ Hybridization, Fluorescence: A type of IN SITU HYBRIDIZATION in which target sequences are stained with fluorescent dye so their location and size can be determined using fluorescence microscopy. This staining is sufficiently distinct that the hybridization signal can be seen both in metaphase spreads and in interphase nuclei.Immunoglobulin D: An immunoglobulin which accounts for less than 1% of plasma immunoglobulin. It is found on the membrane of many circulating B LYMPHOCYTES.Neoplasm Proteins: Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm.Neoplasms, Plasma Cell: Neoplasms associated with a proliferation of a single clone of PLASMA CELLS and characterized by the secretion of PARAPROTEINS.Drug Synergism: The action of a drug in promoting or enhancing the effectiveness of another drug.Chromosome Aberrations: Abnormal number or structure of chromosomes. Chromosome aberrations may result in CHROMOSOME DISORDERS.Osteoclasts: A large multinuclear cell associated with the BONE RESORPTION. An odontoclast, also called cementoclast, is cytomorphologically the same as an osteoclast and is involved in CEMENTUM resorption.Antibodies, Monoclonal: Antibodies produced by a single clone of cells.Xenograft Model Antitumor Assays: In vivo methods of screening investigative anticancer drugs, biologic response modifiers or radiotherapies. Human tumor tissue or cells are transplanted into mice or rats followed by tumor treatment regimens. A variety of outcomes are monitored to assess antitumor effectiveness.Immunoglobulins: Multi-subunit proteins which function in IMMUNITY. They are produced by B LYMPHOCYTES from the IMMUNOGLOBULIN GENES. They are comprised of two heavy (IMMUNOGLOBULIN HEAVY CHAINS) and two light chains (IMMUNOGLOBULIN LIGHT CHAINS) with additional ancillary polypeptide chains depending on their isoforms. The variety of isoforms include monomeric or polymeric forms, and transmembrane forms (B-CELL ANTIGEN RECEPTORS) or secreted forms (ANTIBODIES). They are divided by the amino acid sequence of their heavy chains into five classes (IMMUNOGLOBULIN A; IMMUNOGLOBULIN D; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M) and various subclasses.Hematopoietic Stem Cell Mobilization: The release of stem cells from the bone marrow into the peripheral blood circulation for the purpose of leukapheresis, prior to stem cell transplantation. Hematopoietic growth factors or chemotherapeutic agents often are used to stimulate the mobilization.Peripheral Blood Stem Cell Transplantation: Transplantation of stem cells collected from the peripheral blood. It is a less invasive alternative to direct marrow harvesting of hematopoietic stem cells. Enrichment of stem cells in peripheral blood can be achieved by inducing mobilization of stem cells from the BONE MARROW.Transplantation Conditioning: Preparative treatment of transplant recipient with various conditioning regimens including radiation, immune sera, chemotherapy, and/or immunosuppressive agents, prior to transplantation. Transplantation conditioning is very common before bone marrow transplantation.Signal Transduction: The intracellular transfer of information (biological activation/inhibition) through a signal pathway. In each signal transduction system, an activation/inhibition signal from a biologically active molecule (hormone, neurotransmitter) is mediated via the coupling of a receptor/enzyme to a second messenger system or to an ion channel. Signal transduction plays an important role in activating cellular functions, cell differentiation, and cell proliferation. Examples of signal transduction systems are the GAMMA-AMINOBUTYRIC ACID-postsynaptic receptor-calcium ion channel system, the receptor-mediated T-cell activation pathway, and the receptor-mediated activation of phospholipases. Those coupled to membrane depolarization or intracellular release of calcium include the receptor-mediated activation of cytotoxic functions in granulocytes and the synaptic potentiation of protein kinase activation. Some signal transduction pathways may be part of larger signal transduction pathways; for example, protein kinase activation is part of the platelet activation signal pathway.Angiogenesis Inhibitors: Agents and endogenous substances that antagonize or inhibit the development of new blood vessels.Lymphoma: A general term for various neoplastic diseases of the lymphoid tissue.Immunoglobulin A: Represents 15-20% of the human serum immunoglobulins, mostly as the 4-chain polymer in humans or dimer in other mammals. Secretory IgA (IMMUNOGLOBULIN A, SECRETORY) is the main immunoglobulin in secretions.Hematologic Neoplasms: Neoplasms located in the blood and blood-forming tissue (the bone marrow and lymphatic tissue). The commonest forms are the various types of LEUKEMIA, of LYMPHOMA, and of the progressive, life-threatening forms of the MYELODYSPLASTIC SYNDROMES.B-Lymphocytes: Lymphoid cells concerned with humoral immunity. They are short-lived cells resembling bursa-derived lymphocytes of birds in their production of immunoglobulin upon appropriate stimulation.Osteonecrosis: Death of a bone or part of a bone, either atraumatic or posttraumatic.Induction Chemotherapy: Initial drug treatment designed to bring about REMISSION INDUCTION. It is typically a short-term and high-dose drug treatment that is followed by CONSOLIDATION CHEMOTHERAPY and then MAINTENANCE CHEMOTHERAPY.Retrospective Studies: Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.Time Factors: Elements of limited time intervals, contributing to particular results or situations.Cell Division: The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION.Oxides: Binary compounds of oxygen containing the anion O(2-). The anion combines with metals to form alkaline oxides and non-metals to form acidic oxides.

Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. (1/5264)

Interleukin 6 (IL-6) is the major survival factor for myeloma tumor cells and induces signaling through the STAT proteins. We report that one STAT family member, Stat3, is constitutively activated in bone marrow mononuclear cells from patients with multiple myeloma and in the IL-6-dependent human myeloma cell line U266. Moreover, U266 cells are inherently resistant to Fas-mediated apoptosis and express high levels of the antiapoptotic protein Bcl-xL. Blocking IL-6 receptor signaling from Janus kinases to the Stat3 protein inhibits Bcl-xL expression and induces apoptosis, demonstrating that Stat3 signaling is essential for the survival of myeloma tumor cells. These findings provide evidence that constitutively activated Stat3 signaling contributes to the pathogenesis of multiple myeloma by preventing apoptosis.  (+info)

Insertion of excised IgH switch sequences causes overexpression of cyclin D1 in a myeloma tumor cell. (2/5264)

Oncogenes are often dysregulated in B cell tumors as a result of a reciprocal translocation involving an immunoglobulin locus. The translocations are caused by errors in two developmentally regulated DNA recombination processes: V(D)J and IgH switch recombination. Both processes share the property of joining discontinuous sequences from one chromosome and releasing intervening sequences as circles that are lost from progeny cells. Here we show that these intervening sequences may instead insert in the genome and that during productive IgH mu-epsilon switch recombination in U266 myeloma tumor cells, a portion of the excised IgH switch intervening sequences containing the 3' alpha-1 enhancer has inserted on chromosome 11q13, resulting in overexpression of the adjacent cyclin D1 oncogene.  (+info)

Bone marrow angiogenesis and mast cell density increase simultaneously with progression of human multiple myeloma. (3/5264)

Immunohistochemical, cytochemical and ultrastructural data showing vivid angiogenesis and numerous mast cells (MCs) in the bone marrow of 24 patients with active multiple myeloma (MM) compared with 34 patients with non-active MM and 22 patients with monoclonal gammopathy of undetermined significance (MGUS) led us to hypothesize that angiogenesis parallels progression of MM, and that MCs participate in its induction via angiogenic factors in their secretory granules.  (+info)

Detection of Kaposi's sarcoma herpesvirus DNA sequences in multiple myeloma bone marrow stromal cells. (4/5264)

Whether Kaposi's sarcoma herpesvirus (KSHV) is associated with multiple myeloma (MM) remains controversial. We assayed for KSHV DNA sequences in long-term bone marrow stromal cells (BMSCs) from 26 patients with MM and 4 normal donors. Polymerase chain reaction (PCR) using primers which amplify a KSHV gene sequence to yield a 233-bp fragment (KS330233 within open reading frame 26) was negative in all cases. Aliquots of these PCR products were used as templates in subsequent nested PCR, with primers that amplify a 186-bp product internal to KS330233. BMSCs from 24 of 26 (92%) patients with MM and 1 of 4 normal donors were KSHV PCR+. DNA sequence analyses showed interpatient specific mutations (2 to 3 bp). Both Southern blot and sequence analyses confirmed the specificity of PCR results. The presence of the KSHV gene sequences was further confirmed by amplifying T 1.1 (open reading frame [ORF] K7) and viral cyclin D (ORF 72), two other domains within the KSHV genome. Immunohistochemical studies of KSHV PCR+ MM BMSCs demonstrate expression of dendritic cell (DC) lineage markers (CD68, CD83, and fascin). Serological studies for the presence of KSHV lytic or latent antibodies were performed using sera from 53 MM patients, 12 normal donors, and 5 human immunodeficiency virus (HIV)/KSHV+ patients. No lytic or latent antibodies were present in sera from either MM patients or normal donors. Taken together, these findings show that KSHV DNA sequences are detectable in BMSCs from the majority of MM patients, but that serologic responses to KSHV are not present. Ongoing studies are defining whether the lack of antibody response is caused by the absence of ongoing infection, the presence of a novel viral strain associated with MM, or underlying immunodeficiency in these patients.  (+info)

Bone marrow and peripheral blood dendritic cells from patients with multiple myeloma are phenotypically and functionally normal despite the detection of Kaposi's sarcoma herpesvirus gene sequences. (5/5264)

Multiple myeloma (MM) cells express idiotypic proteins and other tumor-associated antigens which make them ideal targets for novel immunotherapeutic approaches. However, recent reports show the presence of Kaposi's sarcoma herpesvirus (KSHV) gene sequences in bone marrow dendritic cells (BMDCs) in MM, raising concerns regarding their antigen-presenting cell (APC) function. In the present study, we sought to identify the ideal source of DCs from MM patients for use in vaccination approaches. We compared the relative frequency, phenotype, and function of BMDCs or peripheral blood dendritic cells (PBDCs) from MM patients versus normal donors. DCs were derived by culture of mononuclear cells in the presence of granulocyte-macrophage colony-stimulating factor and interleukin-4. The yield as well as the pattern and intensity of Ag (HLA-DR, CD40, CD54, CD80, and CD86) expression were equivalent on DCs from BM or PB of MM patients versus normal donors. Comparison of PBDCs versus BMDCs showed higher surface expression of HLA-DR (P =.01), CD86 (P =. 0003), and CD14 (P =.04) on PBDCs. APC function, assessed using an allogeneic mixed lymphocyte reaction (MLR), demonstrated equivalent T-cell proliferation triggered by MM versus normal DCs. Moreover, no differences in APC function were noted in BMDCs compared with PBDCs. Polymerase chain reaction (PCR) analysis of genomic DNA from both MM patient and normal donor DCs for the 233-bp KSHV gene sequence (KS330233) was negative, but nested PCR to yield a final product of 186 bp internal to KS330233 was positive in 16 of 18 (88.8%) MM BMDCs, 3 of 8 (37.5%) normal BMDCs, 1 of 5 (20%) MM PBDCs, and 2 of 6 (33.3%) normal donor PBDCs. Sequencing of 4 MM patient PCR products showed 96% to 98% homology to the published KSHV gene sequence, with patient specific mutations ruling out PCR artifacts or contamination. In addition, KHSV-specific viral cyclin D (open reading frame [ORF] 72) was amplified in 2 of 5 MM BMDCs, with sequencing of the ORF 72 amplicon revealing 91% and 92% homology to the KSHV viral cyclin D sequence. These sequences again demonstrated patient specific mutations, ruling out contamination. Therefore, our studies show that PB appears to be the preferred source of DCs for use in vaccination strategies due to the ready accessibility and phenotypic profile of PBDCs, as well as the comparable APC function and lower detection rate of KSHV gene sequences compared with BMDCs. Whether active KSHV infection is present and important in the pathophysiology of MM remains unclear; however, our study shows that MMDCs remain functional despite the detection of KSHV gene sequences.  (+info)

Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. (6/5264)

Integrin-mediated adhesion influences cell survival and may prevent programmed cell death. Little is known about how drug-sensitive tumor cell lines survive initial exposures to cytotoxic drugs and eventually select for drug-resistant populations. Factors that allow for cell survival following acute cytotoxic drug exposure may differ from drug resistance mechanisms selected for by chronic drug exposure. We show here that drug-sensitive 8226 human myeloma cells, demonstrated to express both VLA-4 (alpha4beta1) and VLA-5 (alpha5beta1) integrin fibronectin (FN) receptors, are relatively resistant to the apoptotic effects of doxorubicin and melphalan when pre-adhered to FN and compared with cells grown in suspension. This cell adhesion mediated drug resistance, or CAM-DR, was not due to reduced drug accumulation or upregulation of anti-apoptotic Bcl-2 family members. As determined by flow cytometry, myeloma cell lines selected for drug resistance, with either doxorubicin or melphalan, overexpress VLA-4. Functional assays revealed a significant increase in alpha4-mediated cell adhesion in both drug-resistant variants compared with the drug-sensitive parent line. When removed from selection pressure, drug-resistant cell lines reverted to a drug sensitive and alpha4-low phenotype. Whether VLA-4-mediated FN adhesion offers a survival advantage over VLA-5-mediated adhesion remains to be determined. In conclusion, we have demonstrated that FN-mediated adhesion confers a survival advantage for myeloma cells acutely exposed to cytotoxic drugs by inhibiting drug-induced apoptosis. This finding may explain how some cells survive initial drug exposure and eventually express classical mechanisms of drug resistance such as MDR1 overexpression.  (+info)

Overexpression of the receptor for hyaluronan-mediated motility (RHAMM) characterizes the malignant clone in multiple myeloma: identification of three distinct RHAMM variants. (7/5264)

The receptor for hyaluronan (HA)-mediated motility (RHAMM) controls motility by malignant cells in myeloma and is abnormally expressed on the surface of most malignant B and plasma cells in blood or bone marrow (BM) of patients with multiple myeloma (MM). RHAMM cDNA was cloned and sequenced from the malignant B and plasma cells comprising the myeloma B lineage hierarchy. Three distinct RHAMM gene products, RHAMMFL, RHAMM-48, and RHAMM-147, were cloned from MM B and plasma cells. RHAMMFL was 99% homologous to the published sequence of RHAMM. RHAMM-48 and RHAMM-147 variants align with RHAMMFL, but are characterized by sequence deletions of 48 bp (16 amino acids [aa]) and 147 bp (49 aa), respectively. The relative frequency of these RHAMM transcripts in MM plasma cells was determined by cloning of reverse-transcriptase polymerase chain reaction (RT-PCR) products amplified from MM plasma cells. Of 115 randomly picked clones, 49% were RHAMMFL, 47% were RHAMM-48, and 4% were RHAMM-147. All of the detected RHAMM variants contain exon 4, which is alternatively spliced in murine RHAMM, and had only a single copy of the exon 8 repeat sequence detected in murine RHAMM. RT-PCR analysis of sorted blood or BM cells from 22 MM patients showed that overexpression of RHAMM variants is characteristic of MM B cells and BM plasma cells in all patients tested. RHAMM also appeared to be overexpressed in B lymphoma and B-chronic lymphocytic leukemia (CLL) cells. In B cells from normal donors, RHAMMFL was only weakly detectable in resting B cells from five of eight normal donors or in chronically activated B cells from three patients with Crohn's disease. RHAMM-48 was detectable in B cells from one of eight normal donors, but was undetectable in B cells of three donors with Crohn's disease. RHAMM-147 was undetectable in normal and Crohn's disease B cells. In situ RT-PCR was used to determine the number of individual cells with aggregate RHAMM transcripts. For six patients, 29% of BM plasma cells and 12% of MM B cells had detectable RHAMM transcripts, while for five normal donors, only 1. 2% of B cells expressed RHAMM transcripts. This work suggests that RHAMMFL, RHAMM-48, and RHAMM-147 splice variants are overexpressed in MM and other B lymphocyte malignancies relative to resting or in vivo-activated B cells, raising the possibility that RHAMM and its variants may contribute to the malignant process in B-cell malignancies such as lymphoma, CLL, and MM.  (+info)

Ibandronate reduces osteolytic lesions but not tumor burden in a murine model of myeloma bone disease. (8/5264)

We determined the effects of the potent bisphosphonate ibandronate in a murine model of human myeloma bone disease. In this model, bone lesions typical of the human disease develop in mice following inoculation of myeloma cells via the tail vein. Treatment with ibandronate (4 micrograms per mouse per day) significantly reduced the occurrence of osteolytic bone lesions in myeloma-bearing mice. However, ibandronate did not prevent the mice from developing hindlimb paralysis and did not produce a detectable effect on survival. There was no significant effect of ibandronate on total myeloma cell burden, as assessed by morphometric measurements of myeloma cells in the bone marrow, liver, and spleen, or by measurement of serum IgG2b levels. These results support clinical findings that bisphosphonates may be useful for the treatment of myeloma-associated bone destruction, but suggest that other therapies are also required to reduce tumor growth.  (+info)

International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease.<...International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease.<...
TY - JOUR. T1 - International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease.. AU - Terpos, Evangelos. AU - Morgan, Gareth. AU - Dimopoulos, Meletios A.. AU - Drake, Matthew M. AU - Lentzsch, Suzanne. AU - Raje, Noopur. AU - Sezer, Orhan. AU - García-Sanz, Ramón. AU - Shimizu, Kazuyuki. AU - Turesson, Ingemar. AU - Reiman, Tony. AU - Jurczyszyn, Artur. AU - Merlini, Giampaolo. AU - Spencer, Andrew. AU - Leleu, Xavier. AU - Cavo, Michele. AU - Munshi, Nikhil. AU - Rajkumar, S Vincent. AU - Durie, Brian G M. AU - Roodman, G. David. PY - 2013/6/20. Y1 - 2013/6/20. N2 - The aim of the International Myeloma Working Group was to develop practice recommendations for the management of multiple myeloma (MM) -related bone disease. An interdisciplinary panel of clinical experts on MM and myeloma bone disease developed recommendations based on published data through August 2012. Expert consensus was used to propose additional recommendations in situations ...
Multiple Myeloma Treatment Market Is Expected To Reach USD 21,221.8 Mn By 2025 - Credence Research | Michigan News UpdatesMultiple Myeloma Treatment Market Is Expected To Reach USD 21,221.8 Mn By 2025 - Credence Research | Michigan News Updates
The latest market report published by Credence Research, Inc. "Global Multiple Myeloma Treatment Market - Growth, Share, Opportunities, Competitive Analysis, and Forecast, 2017 - 2025," the Multiple Myeloma Treatment market was valued at USD 8,398.3 Mn in 2016, and is expected to reach USD 21,221.8 Mn by 2025, expanding at a CAGR of 11.0% from 2017 to 2025.. Browse the full report Multiple Myeloma Treatment Market - Growth, Share, Opportunities, Competitive Analysis, and Forecast, 2017 - 2025 at http://www.credenceresearch.com/report/multiple-myeloma-treatment-market. Market Insights. Multiple myeloma treatment options have developed significantly over the last decade. Novel multiple myeloma treatments have provided efficient survival rates among myeloma patients. It has been also observed that the upcoming drug pipeline of multiple myeloma is promising, biological drugs and stem cell based therapies are expected to drive the market in the near future. The key players operating in this industry ...
Molecular characterization of human multiple myeloma cell lines by integrative genomics : insights into the biology of the...Molecular characterization of human multiple myeloma cell lines by integrative genomics : insights into the biology of the...
To investigate the patterns of genetic lesions in a panel of 23 human multiple myeloma cell lines (HMCLs), we made a genomic integrative analysis involving FISH, and both gene expression and genome-wide profiling approaches. The expression profiles of the genes targeted by the main IGH translocations showed that the WHSC1/MMSET gene involved in t(4;14)(p16;q32) was expressed at different levels in all of the HMCLs, and that the expression of the MAF gene was not restricted to the HMCLs carrying t(14;16)(q32;q23). Supervised analyses identified a limited number of genes specifically associated with t(4;14) and involved in different biological processes. The signature related to MAF/MAFB expression included the known MAF target genes CCND2 and ITGB7, as well as genes controlling cell shape and cell adhesion. Genome-wide DNA profiling allowed the identification of a gain on chromosome arm 1q in 88% of the analyzed cell lines, together with recurrent gains on 8q, 18q, 7q, and 20q; the most frequent ...
NCCN Guidelines for Patients® | Multiple MyelomaNCCN Guidelines for Patients® | Multiple Myeloma
43 NCCN Guidelines for Patients ® : Multiple Myeloma, 2018 4 Treatment guide Active (symptomatic) multiple myeloma Active (symptomatic) multiple myeloma Guide 5 shows the primary treatment options for multiple myeloma that is causing symptoms and follow-up tests. Myeloma that is causing symptoms is called active myeloma or symptomatic myeloma. Primary treatment is the first treatment given to try to rid your body of cancer. Primary treatment for active myeloma includes systemic therapies. Systemic therapy travels in your body to treat more than one area of cancer. This type of treatment includes chemotherapy, targeted therapy, and steroids. These drugs may be given alone or in combination. Follow-up tests are usually done after 1 to 2 cycles of treatment to see whether or not the treatment is working or if the disease is progressing (getting worse). Treatment for active myeloma may or may not include a stem cell transplant. A stem cell transplant is not a good treatment option for everyone. ...
Normalizing the bone marrow microenvironment with p38 inhibitor reduces multiple myeloma cell proliferation and adhesion and...Normalizing the bone marrow microenvironment with p38 inhibitor reduces multiple myeloma cell proliferation and adhesion and...
TY - JOUR. T1 - Normalizing the bone marrow microenvironment with p38 inhibitor reduces multiple myeloma cell proliferation and adhesion and suppresses osteoclast formation. AU - Nguyen, Aaron N.. AU - Stebbins, Elizabeth G.. AU - Henson, Margaret. AU - OYoung, Gilbert. AU - Choi, Sun J.. AU - Quon, Diana. AU - Damm, Debby. AU - Reddy, Mamatha. AU - Ma, Jing Y.. AU - Haghnazari, Edwin. AU - Kapoun, Ann M.. AU - Medicherla, Satyanarayana. AU - Protter, Andy. AU - Schreiner, George F.. AU - Kurihara, Noriyoshi. AU - Anderson, Judy. AU - Roodman, G. David. AU - Navas, Tony A.. AU - Higgins, Linda S.. PY - 2006/6/10. Y1 - 2006/6/10. N2 - The multiple myeloma (MM) bone marrow (BM) microenvironment plays a critical role in supporting tumor growth and survival as well as in promoting formation of osteolytic lesions. Recent results suggest that the p38 mitogen-activated protein kinase (MAPK) is an important factor in maintaining this activated environment. In this report, we demonstrate that the p38α ...
Kyprolis® Significantly Improves Overall Survival Compared To Velcade® In Relapsed Or Refractory Multiple Myeloma - UNM...Kyprolis® Significantly Improves Overall Survival Compared To Velcade® In Relapsed Or Refractory Multiple Myeloma - UNM...
The ENDEAVOR trial results were updated at the 16th International Myeloma Workshop in New Delhi. The trial demonstrated that Kyprolis (Carfilzomib) not only significantly extended progression-free survival compared to Velcade (Bortezomib), but also overall improved overall survival, making it a clinically meaningful advance in the treatment of relapsed or refractory multiple myeloma. Patients with relapsed or refractory multiple myeloma treated with Kyprolis® and dexamethasone lived 7.6 months longer than those treated with Velcade® and dexamethasone.1. Multiple myeloma is a cancer of plasma cells, which are a special type of white blood cell that are part of the bodys immune system. In the U.S., approximately 70,000 people are living with multiple myeloma and approximately 24,000 new individuals are diagnosed annually. Patients with multiple myeloma have increased numbers of abnormal plasma cells that may produce increased quantities of dysfunctional antibodies detectable in the blood and/or ...
Guidelines on the diagnosis and management of multiple myeloma treatment: Associacao Brasileira de Hematologia e...Guidelines on the diagnosis and management of multiple myeloma treatment: Associacao Brasileira de Hematologia e...
References. 1. Centre for Evidence Based Medicine [Internet]. Oxford: University of Oxford; 2011. [cited 2012 Nov 21]. Available from: http:// www.cebm.net. [ Links ] 2. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364(11):1046-60. Comment in: N Engl J Med. 2011;364(24):2364; author reply 2364. [ Links ] 3. Hungria VT, Maiolino A, Martinez G, Colleoni GW, Coelho EO, Rocha L, Nunes R, Bittencourt R, Oliveira LC, Faria RM, Pasquini R, Magalhães SM, Souza CA, Pinto Neto JV, Barreto L, Andrade E, Portella M do S, Bolejack V, Durie BG; International Myeloma Working Group Latin America. Confirmation of the utility of the International Staging System and identification of a unique pattern of disease in Brazilian patients with multiple myeloma. Haematologica 2008;93(5):791-2. [ Links ] 4. Korde N, Kristinsson SY, Landgren O. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM): novel biological insights and development of early treatment ...
Clodronate-Liposome Mediated Macrophage Depletion Abrogates Multiple Myeloma Tumor Establishment In Vivo - SAHMRIClodronate-Liposome Mediated Macrophage Depletion Abrogates Multiple Myeloma Tumor Establishment In Vivo - SAHMRI
TY - JOUR. T1 - Clodronate-Liposome Mediated Macrophage Depletion Abrogates Multiple Myeloma Tumor Establishment In Vivo. AU - Opperman, Khatora S.. AU - Vandyke, Kate. AU - Clark, Kimberley C.. AU - Coulter, Elizabeth A.. AU - Hewett, Duncan R.. AU - Mrozik, Krzysztof M.. AU - Schwarz, Nisha. AU - Evdokiou, Andreas. AU - Croucher, Peter I.. AU - Psaltis, Peter. AU - Noll, Jacqueline E.. AU - Zannettino, Andrew. PY - 2019/8/1. Y1 - 2019/8/1. N2 - Multiple myeloma is a fatal plasma cell malignancy that is reliant on the bone marrow microenvironment. The bone marrow is comprised of numerous cells of mesenchymal and hemopoietic origin. Of these, macrophages have been implicated to play a role in myeloma disease progression, angiogenesis, and drug resistance; however, the role of macrophages in myeloma disease establishment remains unknown. In this study, the antimyeloma efficacy of clodronate-liposome treatment, which globally and transiently depletes macrophages, was evaluated in the ...
PLOS ONE: Inhibition of Fatty Acid Metabolism Reduces Human Myeloma Cells ProliferationPLOS ONE: Inhibition of Fatty Acid Metabolism Reduces Human Myeloma Cells Proliferation
Multiple myeloma is a haematological malignancy characterized by the clonal proliferation of plasma cells. It has been proposed that targeting cancer cell metabolism would provide a new selective anticancer therapeutic strategy. In this work, we tested the hypothesis that inhibition of β-oxidation and de novo fatty acid synthesis would reduce cell proliferation in human myeloma cells. We evaluated the effect of etomoxir and orlistat on fatty acid metabolism, glucose metabolism, cell cycle distribution, proliferation, cell death and expression of G1/S phase regulatory proteins in myeloma cells. Etomoxir and orlistat inhibited β-oxidation and de novo fatty acid synthesis respectively in myeloma cells, without altering significantly glucose metabolism. These effects were associated with reduced cell viability and cell cycle arrest in G0/G1. Specifically, etomoxir and orlistat reduced by 40-70% myeloma cells proliferation. The combination of etomoxir and orlistat resulted in an additive inhibitory effect
Quality of Life in Multiple Myeloma Patients Treated With Bortezomib - Tabular View - ClinicalTrials.govQuality of Life in Multiple Myeloma Patients Treated With Bortezomib - Tabular View - ClinicalTrials.gov
Many clinical studies for the treatment of multiple myeloma have been conducted in Korea, but none of them have evaluated the improvement in the quality of life in patients with multiple myeloma. Most study variables used to evaluate the quality of life of patients with multiple myeloma are subjective and limited. This study will observe the degree of change in the quality of life in patients with multiple myeloma before and after bortezomib administration by using EORTC-C30 (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core30) and EQ-5D (EuroQol-5 Dimensions), validated research instruments used to measure the quality of life in cancer patients and consequently will provide fundamental data regarding the quality of life in patients with multiple myeloma.. Observational Study - No investigational drug ...
FDA Approves Celgenes Pomalyst For Advanced Multiple Myeloma - Quick FactsFDA Approves Celgene's Pomalyst For Advanced Multiple Myeloma - Quick Facts
Celgene Corp. (CELG) announced Friday that the U.S. Food and Drug Administration or FDA has approved POMALYST brand therapy (pomalidomide) for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy.
Paper: Overall Survival of Relapsed/Refractory Multiple Myeloma Patients Treated with Carfilzomib and Dexamethasone Vs...Paper: Overall Survival of Relapsed/Refractory Multiple Myeloma Patients Treated with Carfilzomib and Dexamethasone Vs...
Background: Elderly patients with multiple myeloma are a challenging population to treat, and there is a need for effective treatment options. Carfilzomib, a selective proteasome inhibitor, is approved in the United States and other countries for the treatment of relapsed or refractory multiple myeloma (RRMM). A subgroup analysis of interim results from the randomized, phase 3 ENDEAVOR study showed that carfilzomib (56 mg/m2) and dexamethasone (Kd56) resulted in longer median progression-free survival (PFS) and higher overall response rates (ORRs) than bortezomib and dexamethasone (Vd) in patients with RRMM, regardless of age (Table; Ludwig et al, Leuk Lymphoma. 2017;58:2501-2504). Mature overall survival (OS) data has recently been reported from ENDEAVOR and demonstrated that Kd56 resulted in statistically and clinically significant improvement in OS compared with Vd in the intention-to-treat (ITT) population (median, 47.6 months vs 40.0 months; hazard ratio [HR], 0.791; 95% confidence interval ...
bestway: What Is the, Multiple Myeloma Life Expectancybestway: What Is the, Multiple Myeloma Life Expectancy
I have often said , and everyone is probably tired of hearing that a multiple myeloma qualified professional and a well-informed patient can extend your life expectancy. If you listen to Paula multiple myeloma life expectancy, has followed this formula to the letter. He had a first opinion , then a second opinion, and then a third opinion. He contacted the International Monetary Fund (International Myeloma Foundation ) multiple myeloma life expectancy, became a member of the group, and a leader of the group. He chose a great doctor and a treatment of myeloma. His doctor was none other than David S. Siegel, MD , Ph.D., director of the Division of Multiple Myeloma at John There Cancer Center, Hackensack University Medical Center. Before that , he spent years in the center MSN and worked hand in hand with Dr. Bart Brogue . In 1999 , MSN was and is considered one of the best centers in the world myeloma . So Paula has chosen , and he needed it multiple myeloma life expectancy. He discovered that he ...
EHA 2017: Ixazomib Plus Lenalidomide/Dexamethasone in Newly Diagnosed Multiple Myeloma With No Stem Cell Transplant, Followed...EHA 2017: Ixazomib Plus Lenalidomide/Dexamethasone in Newly Diagnosed Multiple Myeloma With No Stem Cell Transplant, Followed...
Data from two phase I/II clinical trials evaluating ixazomib (Ninlaro) in patients with newly diagnosed multiple myeloma was presented at the 2017 European Hematology Association (EHA) Annual Meeting (Abstracts S408, S780). Both studies evaluated ixazomib plus lenalidomide (Revlimid) and dexamethasone in newly diagnosed patients with multiple myeloma who did not undergo stem cell transplant, followed by maintenance with single-agent ixazomib. Ixazomib is currently not approved for the treatment of newly diagnosed multiple myeloma or in the maintenance setting.. "Despite recent progress, multiple myeloma remains a rare, devastating, and incurable hematologic cancer.… These phase I/II data demonstrate the potential use of ixazomib in combination with lenalidomide/dexamethasone in newly diagnosed multiple myeloma and as a single-agent maintenance therapy, which resulted in patients achieving deepening responses with continual use of the treatment. Ixazomibs efficacy and safety profile-coupled ...
A novel role of IL-17-producing lymphocytes in mediating lytic bone disease in multiple myeloma<...A novel role of IL-17-producing lymphocytes in mediating lytic bone disease in multiple myeloma<...
TY - JOUR. T1 - A novel role of IL-17-producing lymphocytes in mediating lytic bone disease in multiple myeloma. AU - Noonan, Kimberly. AU - Marchionni, Luigi. AU - Anderson, Judy. AU - Pardoll, Drew. AU - Roodman, G. David. AU - Borrello, Ivan. PY - 2010/11/4. Y1 - 2010/11/4. N2 - Osteoclast (OC)-mediated lytic bone disease remains a cause of major morbidity in multiple myeloma. Here we demonstrate the critical role of interleukin-17-producing marrow infiltrating lymphocytes (MILs) in OC activation and development of bone lesions in myeloma patients. Unlike MILs from normal bone marrow, myeloma MILs possess few regulatory T cells (Tregs) and demonstrate an interleukin-17 phenotype that enhances OC activation. In univariate analyses of factors mediating bone destruction, levels of cytokines that selectively induce and maintain the Th17 phenotype tightly correlated with the extent of bone disease in myeloma. In contrast, MILs activated under conditions that skew toward a Th1 phenotype ...
A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients - Full Text...A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients - Full Text...
Multiple myeloma (MM), a plasma cell dyscrasia, is the most common primary malignancy of the bone marrow.The etiology of myeloma is largely unknown, although genetic predisposition and environmental factors have been speculated. MM arises from malignant plasma cells that clonally expand and accumulate in the bone marrow. These clonal plasma cells produce high levels of monoclonal immunoglobulins. Plasma cell dyscrasias are classified as monoclonal gammopathy of undetermined significance, solitary plasmacytoma, smoldering myeloma, active myeloma, extra-skeletal myeloma, or plasma cell leukemia.. In 2015 an estimated 26,850 adults (14,090 men and 12,760 women) in the United States will be diagnosed with multiple myeloma. It is estimated that 11,240 deaths (6,240 men and 5,000 women) from this disease will occur this year.. In recent years, new and more effective drugs have become available for the treatment of MM. Such drugs have been evaluated together and in combination with older agents, ...
Toll-Like Receptors in Human Multiple Myeloma: New Insight into Inflammation-Related Pathogenesis | Bentham ScienceToll-Like Receptors in Human Multiple Myeloma: New Insight into Inflammation-Related Pathogenesis | Bentham Science
Title:Toll-Like Receptors in Human Multiple Myeloma: New Insight into Inflammation-Related Pathogenesis. VOLUME: 14 ISSUE: 4. Author(s):J. Abdi, J. Garssen and F. Redegeld. Affiliation:Division of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, P.O. Box 80082, 3508 TB Utrecht, The Netherlands.. Keywords:Bone marrow, drug resistance, inflammation, multiple myeloma, toll like receptors.. Abstract:Multiple myeloma (MM) is a clonal neoplasm characterized by expansion of malignant plasma cells in the bone marrow causing various complications including osteolytic lesions and impaired immune function. It has recently been reported that human myeloma cells express multiple Toll-like receptors (TLRs), and their activation-induced functional responses show heterogeneity among cell lines and patient samples. TLRs are critical germ-line encoded molecules expressed in immune cells as well as in a variety of cancer cells. In multiple myeloma, they may ...
Recurrent Multiple MyelomaRecurrent Multiple Myeloma
The introduction of three new drugs for multiple myeloma - Velcade® (bortezomib), Revlimid® (lenalidomide), and Thalomid® (thalidomide) - has improved outcomes among patients with newly-diagnosed multiple myeloma as well as patients with relapsed or refractory multiple myeloma.. Velcade® (bortezomib): Velcade is a targeted therapy that inhibits the activities of a group of proteins, called proteasomes. These proteins are found in virtually all cells, but are particularly important for allowing myeloma cancer cells to survive and grow. By inhibiting the proteasomes, Velcade kills cancer cells and reduced overall cancer growth.. Important support for the use of Velcade in the treatment of relapsed multiple myeloma came from a phase III clinical trial known as the Assessment of Proteasome Inhibition for Extending Remissions (APEX) trial. The study enrolled more than 600 patients with relapsed multiple myeloma. Half the patients were treated with Velcade and half were treated with high-dose ...
What is end stage multiple myeloma? | Reference.comWhat is end stage multiple myeloma? | Reference.com
End stage multiple myeloma is the final stage of advanced multiple myeloma. According to MedlinePlus, the symptoms of end stage multiple myeloma include vomiting, nausea, urination problems, numbness...
Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era...Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era...
Results The most common sites for extramedullary disease at diagnosis were skin and soft tissue whereas liver involvement was the striking feature in extramedullary disease at disease relapse or progression. Regardless of therapy, extramedullary disease was associated with shorter progression-free and overall survival, as well as the presence of anemia, thrombocytopenia, elevated serum lactate dehydrogenase, cytogenetic abnormalities, and high-risk features in 70-and 80-gene risk models in univariate analysis. Multivariate analysis with logistic regression revealed that this disease feature was more prevalent in patients with an elevated centrosome index, as determined by gene expression profiling, as well as in myeloma molecular subtypes that are more prone to relapse. These include the MF subtype (also called the "MAF" subtype, associated with over-expression of the MAF gene seen with chromosome translocation 14;16 or 14;20) and the PR subtype (also called the "Proliferation" subtype, ...
Supportive Care for Multiple MyelomaSupportive Care for Multiple Myeloma
Bone complications: In 70% of multiple myeloma cases, the bones develop multiple holes, which explains why the disease is referred to as "multiple" myeloma. The holes are referred to as osteolytic lesions, which cause the bones to be fragile and subject to fractures. Osteolytic lesions are caused by the rapid growth of myeloma cells, which push aside normal bone-forming cells, preventing them from repairing general wear and tear of the bones. Under normal circumstances, cells called osteoclasts destroy dead and dying bone. Multiple myeloma causes the secretion of osteoclast-activating factor, a substance that stimulates osteoclasts.. Multiple myeloma involving the bone can cause pain, fracture and other significant problems for patients. Management of bone involvement is an integral part of the overall treatment strategy for multiple myeloma. The first objective of treatment of bone complications is to prevent new bone disease from developing or progression from existing bone lesions to ...
Wave of New Therapies Improve Outcomes for Patients with Multiple Myeloma - Multiple MyelomaWave of New Therapies Improve Outcomes for Patients with Multiple Myeloma - Multiple Myeloma
This article was originally published by Cancer Health New drugs to treat multiple myeloma are producing better results for patients, with fewer side effects.. For many patients with multiple myeloma, a new generation of drugs and drug combinations is producing better outcomes and fewer side effects. In recent months, several novel therapies studied and tested by Dana-Farber scientists have gained approval from the U.S. Food and Drug Administration (FDA) or taken a step toward approval after posting solid results in clinical trials.. The drugs are the fruit of years of research into improving treatment for multiple myeloma, a cancer of white blood cells known as plasma cells in the bone marrow. Many of the new agents are biologically derived - made from substances such as proteins and antibodies found in living things - and target biological mechanisms in a very specific, targeted fashion. Dana-Farber researchers have played a key role in these efforts.. "These are each powerful examples of how ...
The Proteasome Inhibitor PS-341 Markedly Enhances Sensitivity of Multiple Myeloma Tumor Cells to Chemotherapeutic Agents |...The Proteasome Inhibitor PS-341 Markedly Enhances Sensitivity of Multiple Myeloma Tumor Cells to Chemotherapeutic Agents |...
MM patients develop chemoresistance, and increasing the concentrations of cytotoxic drugs fails to significantly improve the therapeutic response. One hypothesis for the development of chemoresistance is related to acquired resistance of the tumor cells to apoptosis (34) , allowing tumors to withstand high levels of chemotherapy. Tumor cells that are resistant to apoptosis also exhibit increased proliferative capacity. Wang et al. (35) reported that activation of NF-κB in response to chemotherapy is a principal mechanism of tumor chemoresistance. Inhibition of such inducible NF-κB activation enhances apoptosis. Increased activity of NF-κB proteins has been reported in solid tumors resistant to chemotherapy (36) . In this report, we found that the activity of NF-κB was elevated in MM tumor cells. The activity of NF-κB appeared to be higher in chemoresistant MM cell lines compared with chemosensitive ones, although the difference was not always consistent between chemosensitive versus ...
Myeloma cells exhibit an increase in proteasome activity and an enhanced response to proteasome inhibition in the bone marrow...Myeloma cells exhibit an increase in proteasome activity and an enhanced response to proteasome inhibition in the bone marrow...
The proteasome inhibitor bortezomib has a striking clinical benefit in patients with multiple myeloma. It is unknown whether the bone marrow microenvironment directly contributes to the dramatic response of myeloma cells to proteasome inhibition in vivo. We have used the well-characterized 5TGM1 murine model of myeloma to investigate myeloma growth within bone and response to the proteasome inhibitor bortezomib in vivo. Myeloma cells freshly isolated from the bone marrow of myeloma-bearing mice were found to have an increase in proteasome activity and an enhanced response to in vitro proteasome inhibition, as compared with pre-inoculation myeloma cells. Treatment of myeloma-bearing mice with bortezomib resulted in a greater reduction in tumor burden when the myeloma cells were located within the bone marrow when compared with extra-osseous sites. Our results demonstrate that myeloma cells exhibit an increase in proteasome activity and an enhanced response to bortezomib treatment when located within the
A mathematical model of bone remodeling dynamics for normal bone cell populations and myeloma bone disease | Biology Direct |...A mathematical model of bone remodeling dynamics for normal bone cell populations and myeloma bone disease | Biology Direct |...
Multiple myeloma is a hematologic malignancy associated with the development of a destructive osteolytic bone disease. Mathematical models are developed for normal bone remodeling and for the dysregulated bone remodeling that occurs in myeloma bone disease. The models examine the critical signaling between osteoclasts (bone resorption) and osteoblasts (bone formation). The interactions of osteoclasts and osteoblasts are modeled as a system of differential equations for these cell populations, which exhibit stable oscillations in the normal case and unstable oscillations in the myeloma case. In the case of untreated myeloma, osteoclasts increase and osteoblasts decrease, with net bone loss as the tumor grows. The therapeutic effects of targeting both myeloma cells and cells of the bone marrow microenvironment on these dynamics are examined. The current model accurately reflects myeloma bone disease and illustrates how treatment approaches may be investigated using such computational approaches. This
Smoldering multiple myeloma risk factors for progression - Forskning - RigshospitaletSmoldering multiple myeloma risk factors for progression - Forskning - Rigshospitalet
TY - JOUR. T1 - Smoldering multiple myeloma risk factors for progression. T2 - a Danish population-based cohort study. AU - Sørrig, Rasmus. AU - Klausen, Tobias W. AU - Salomo, Morten. AU - Vangsted, Annette J. AU - Østergaard, Brian. AU - Gregersen, Henrik. AU - Frølund, Ulf Christian. AU - Andersen, Niels F. AU - Helleberg, Carsten. AU - Andersen, Kristian T. AU - Pedersen, Robert S. AU - Pedersen, Per. AU - Abildgaard, Niels. AU - Gimsing, Peter. AU - Danish Myeloma Study Group. N1 - This article is protected by copyright. All rights reserved.. PY - 2015/12/29. Y1 - 2015/12/29. N2 - Several risk scores for disease progression in Smoldering Multiple Myeloma (SMM) patients have been proposed, however, all have been developed using single center registries. To examine risk factors for time to progression (TTP) to Multiple Myeloma (MM) for SMM we analyzed a nationwide population-based cohort of 321 newly diagnosed SMM patients registered within the Danish Multiple Myeloma Registry between 2005 ...
Robert Kyle, M.D.: Multiple Myeloma Pioneer | Discoverys EdgeRobert Kyle, M.D.: Multiple Myeloma Pioneer | Discovery's Edge
Multiple myeloma is a cancer of the plasma cells. People with the condition have an increase of abnormal plasma cells (myeloma cells) in their bone marrow, monoclonal protein in their blood and, often, osteolytic bone lesions. As the disease progresses, symptoms of anemia, fatigue, weakness, fractures, bone pain, increased blood calcium, kidney problems, recurrent infections and bleeding are common. The median survival rate is three to four years. The American Cancer Society estimates 20,000 people are diagnosed with multiple myeloma in the U.S. each year.. People with MGUS do not have symptoms associated with multiple myeloma. The disorder is diagnosed by laboratory tests that indicate an increase in M proteins in the blood and elevated bone marrow plasma cells.. "I recognized the importance of a having a laboratory that could identify the type of protein and be able to distinguish monoclonal from polyclonal proteins," says Dr. Kyle. "I visited the National Institutes of Health and Columbia ...
DEBATE: Is MRD the new primary goal for multiple myeloma treatment? - Yes - OncologyTubeDEBATE: Is MRD the new primary goal for multiple myeloma treatment? - Yes - OncologyTube
Earn CME: https://naccme.com/program/7312In this presentation from the Looking for One in a Million: Is MRD the New Primary Goal for Multiple Myeloma Treatment? symposium, Dr. C. Ola Landgren argues that MRS is new primary goal for multiple myeloma treatment.© 2018 Imedex, an HMP Company - Multiple Myeloma
IJMS | Free Full-Text | Analytical Criticalities Associated to Different Immunological Methods for Serum Free Light Chain...IJMS | Free Full-Text | Analytical Criticalities Associated to Different Immunological Methods for Serum Free Light Chain...
Current criteria for differential diagnosis of multiple myeloma (MM), Monoclonal gammopathy of undetermined significance (MGUS), and smoldering multiple myeloma (SMM) are included in the 2003 guidelines by the International Myeloma Working Group (IMWG). An updated version was then published in 2014, highlighting the importance of serum free light chain (sFLC) detection, as well as the κ/λ ratio as excellent indicators of clonality. At present, two commercial assays for sFLC quantification are available: the Freelite™ assay and the N-Latex assay. The first was developed by The Binding Site based on a mixture of polyclonal antibodies directed against a variety of FLC epitopes. It may be run on a wide range of nephelometers, as well as on turbidimeters. The second method was developed by Siemens and runs exclusively on Siemens instruments. It employs a probe mixture of mouse monoclonal antibodies. The aim of our study was to evaluate sFLC measurement and calculated κ/λ ratio in 85 patients with
C-reactive protein promotes bone destruction in human myeloma through the CD32-p38 MAPK-Twist axis | Science SignalingC-reactive protein promotes bone destruction in human myeloma through the CD32-p38 MAPK-Twist axis | Science Signaling
Bone destruction is a hallmark of myeloma and affects 80% of patients. Myeloma cells promote bone destruction by activating osteoclasts. In investigating the underlying mechanism, we found that C-reactive protein (CRP), a protein secreted in increased amounts by hepatocytes in response to myeloma-derived cytokines, activated myeloma cells to promote osteoclastogenesis and bone destruction in vivo. In mice bearing human bone grafts and injected with multiple myeloma cells, CRP bound to surface CD32 (also known as FcγRII) on myeloma cells, which activated a pathway mediated by the kinase p38 MAPK and the transcription factor Twist that enhanced the cells secretion of osteolytic cytokines. Furthermore, analysis of clinical samples from newly diagnosed myeloma patients revealed a positive correlation between the amount of serum CRP and the number of osteolytic bone lesions. These findings establish a mechanism by which myeloma cells are activated to promote bone destruction and suggest that CRP ...
multiple myeloma for dummiesmultiple myeloma for dummies
Multiple Myeloma (90) Multiple Myeloma Awareness (36) Bone Marrow Transplant (28) Michigan Football (27) Dominate (25) Myeloma Mondays (24) Stem Cell Transplant (24) Multiple Myeloma Survivor Stories (19) Chemo (15) M-Protein (15) Dr. J (14) MM (12) Dexamethasone (11) BMT (10) Ocean (9) UMHS (9) domiNATION (9) Cancer Kicker (8) Hope (8) IgG (8) M Spike (8) MM Awareness (8) Revlimid (8) Story Time (8) Velcade (8) Cancer Kicker Foundation (7) Chemotherapy (7) Dominate Gear (7) M-Spike (7) Ruby (7) Young with Myeloma (7) Dominate Life (6) Multiple Myeloma Bracelets (6) Thankful Thursdays (6) Cancer Kicker Bracelets (5) Complete Response (5) Dominate Myeloma (5) Doxil (5) Iris (5) Michigan Faithful (5) Phil and Cassie Plus Cancer Show (5) RVDD (5) SCT (5) UAMS (5) Big House Big Heart run (4) Bone Marrow Biopsy (4) CancerKicker (4) Consolidation (4) Constipation (4) Cytoxan (4) ER (4) Infusion Center (4) M Protein (4) MMRF (4) Maintenance Therapy (4) Stem Cell Collection (4) Stomach Lava (4) Survivor ...
c-Met signaling promotes IL-6-induced myeloma cell proliferation - Hov - 2009 - European Journal of Haematology - Wiley Online...c-Met signaling promotes IL-6-induced myeloma cell proliferation - Hov - 2009 - European Journal of Haematology - Wiley Online...
The main finding reported here is that IL-6-induced proliferation may be dependent on c-Met signaling in myeloma cells. The potentiating effect of HGF/c-Met on IL-6 signaling could be explained by two mechanisms: (i) IL-6 increased the level of c-Met on the cell surface of myeloma cells making cells more sensitive to HGF; and (ii) IL-6 relied on HGF/c-Met to fully activate the Ras-MAPK pathway possibly through Shp2 activation.. HGF is found in bone marrow plasma of both healthy subjects and myeloma patients (5), and bone marrow stromal cells constitutively produce HGF (34). Moreover, syndecan-1 binds HGF on the surface of myeloma cells (5) bringing HGF in close proximity of its receptor c-Met. Immunohistochemical staining for HGF on bone marrow biopsies revealed that plasma cells from almost all myeloma patients stained positive for HGF (K. W. Wader, unpublished data). In this context, the IL-6-induced increase in c-Met expression as shown here may become vital for HGF sensitivity and growth ...
Los Angeles Cancer Network » Stages II-III Multiple MyelomaLos Angeles Cancer Network » Stages II-III Multiple Myeloma
The treatment of multiple myeloma is focused on treating the underlying disease (the increased number of abnormal plasma cells). Managing the symptoms and other medical problems resulting from the increased numbers of plasma cells and abnormal proteins is equally important.. The following complications of multiple myeloma have specific treatments available:. Bone complications: In 70% of multiple myeloma cases, the bones develop multiple holes, which explains why the disease is referred to as "multiple" myeloma. The holes are referred to as osteolytic lesions, which cause the bones to be fragile and subject to fractures. Osteolytic lesions are caused by the rapid growth of myeloma cells, which push aside normal bone-forming cells, preventing them from repairing general wear and tear of the bones. Under normal circumstances, cells called osteoclasts destroy dead and dying bone. Multiple myeloma causes the secretion of osteoclast-activating factor, a substance that stimulates ...
Daratumumab Anti-CD38 Monoclonal Antibody Appears Promising For the Treatment of Multiple Myeloma - UNM Comprehensive Cancer...Daratumumab Anti-CD38 Monoclonal Antibody Appears Promising For the Treatment of Multiple Myeloma - UNM Comprehensive Cancer...
An investigational new class of drugs, the anti-CD38 monoclonal antibodies, could be the next major advance in the treatment of multiple myeloma. These findings were presented at the 56th American Hematological Society Annual Meeting and Exposition, December 6-9, 2014, in San Francisco, California.. Multiple myeloma is a cancer of plasma cells, which are a special type of white blood cell that are part of the bodys immune system. In the U.S., approximately 70,000 people are living with multiple myeloma and approximately 24,000 new individuals are diagnosed annually. Patients with multiple myeloma have increased numbers of abnormal plasma cells that may produce increased quantities of dysfunctional antibodies detectable in the blood and/or urine. Patients with multiple myeloma who have become refractory-or resistant-to the drugs Revlimid® (lenalidomide) and Velcade® (bortezomib) have limited treatment options. There is no standard treatment for these patients and they typically have a poor ...
Kyprolis Improves Survival in Recurrent Multiple Myeloma « Broome OncologyKyprolis Improves Survival in Recurrent Multiple Myeloma « Broome Oncology
CancerConnect News: The addition of Kyprolis® (carfilzomib) to the standard treatment regimen, Revlimid® (lenalidomide) and dexamethasone, improves survival for patients with multiple myeloma whose disease progressed or recurred following prior therapies. These results were recently presented at the 2017 annual meeting of the American Society of Hematology (ASH).. About Multiple Myeloma. In the United States alone, approximately 30,000 people will be diagnosed with multiple myeloma in the year 2017. Multiple myeloma is a type of cancer that starts in immune cells called plasma cells. Treatment varies according to the extent or aggressiveness of the disease, as well as the patients other existing medical conditions or ability to tolerate some types of therapies.. Patients with multiple myeloma that has recurred following prior therapy have historically been considered incurable. Fortunately, the recent progress of individualized treatment approaches continues to delay the time to cancer ...
U.S. Food and Drug Administration Approval: Carfilzomib for the Treatment of Multiple Myeloma | Clinical Cancer ResearchU.S. Food and Drug Administration Approval: Carfilzomib for the Treatment of Multiple Myeloma | Clinical Cancer Research
The first proteasome inhibitor approved for treatment of patients with multiple myeloma, bortezomib (Velcade;Millennium/Takeda), a modified dipeptidyl boronic acid, has become one of the most effective therapeutic agents (4). The second approved proteasome inhibitor, carfilzomib, a modified tetrapeptidyl epoxide, differs from bortezomib in structure, activity, and irreversibility of its binding to one of the active sites, the β5 subunit of the 20S proteasome. Preclinical studies had shown that carfilzomib was active against bortezomib-resistant multiple myeloma cell lines (11), and the pivotal trial described above showed its activity in patients with bortezomib-resistant multiple myeloma. Thus, approval of carfilzomib may prove to be another milestone in the treatment of this disease.. Bortezomib was initially approved under the accelerated approval pathway (15). The approval was based on the results of a single-arm trial of 202 patients with relapsed multiple myeloma who had received a median ...
OPUS Würzburg | SearchOPUS Würzburg | Search
Multiple myeloma is a bone marrow plasma cell tumor which is supported by the external growth factors APRIL and IL-6, among others. Recently, we identified eosinophils and megakaryocytes to be functional components of the micro-environmental niches of benign bone marrow plasma cells and to be important local sources of these cytokines. Here, we investigated whether eosinophils and megakaryocytes also support the growth of tumor plasma cells in the MOPC315. BM model for multiple myeloma. As it was shown for benign plasma cells and multiple myeloma cells, IL-6 and APRIL also supported MOPC315. BM cell growth in vitro, IL-5 had no effect. Depletion of eosinophils in vivo by IL-5 blockade led to a reduction of the early myeloma load. Consistent with this, myeloma growth in early stages was retarded in eosinophil-deficient Delta dblGATA-1 mice. Late myeloma stages were unaffected, possibly due to megakaryocytes compensating for the loss of eosinophils, since megakaryocytes were found to be in contact ...
Blog Archives - Multiple Myeloma - Survival Rate Statistics by HospitalBlog Archives - Multiple Myeloma - Survival Rate Statistics by Hospital
What researchers have found is that when you use a proteasome inhibitor, immunomodulator, and steroid, such as in this case RVd (Revlimid, Velcade, and dexamethasone), the response rates are remarkably high. In the Dana Farber led Phase 1/2 multi-center study published in 2010 in Blood, a response rate of 100% with 50% of patients obtaining a complete remission was shown. For those patients in this study that went on to transplant, no advantage in progression free survival at 18 months was observed compared to those who did not undergo transplant . This gave Dana Farber and their partners the impetus to conduct a larger Phase 3 trial, in collaboration with their colleagues in the Intergroupe Francophone du Myelome (IFM), knowing that with such an active regimen of RVd they needed to investigate further what role transplant should take in myeloma treatment. In this current Phase 3 trial they are looking at using the RVd regimen either before stem cell mobilization with chemotherapy with a long ...
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma<...Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma<...
TY - JOUR. T1 - Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma. AU - Palumbo, Giuseppe Antonio. AU - Chanan-Khan, Asher A.. AU - Weisel, Katja. AU - Nooka, Ajay K.. AU - Masszi, Tamas. AU - Beksac, Meral. AU - Spicka, Ivan. AU - Hungria, Vania. AU - Munder, Markus. AU - Mateos, Maria Victoria. AU - Mark, Tomer M. AU - Qi, Ming. AU - Schecter, Jordan. AU - Amin, Himal. AU - Qin, Xiang. AU - Deraedt, William. AU - Ahmadi, Tahamtan. AU - Spencer, Andrew. AU - Sonneveld, Pieter. AU - CASTOR Investigators. PY - 2016/8/25. Y1 - 2016/8/25. N2 - BACKGROUND: Daratumumab, a human IgGκ monoclonal antibody that targets CD38, induces direct and indirect antimyeloma activity and has shown substantial efficacy as monotherapy in heavily pretreated patients with multiple myeloma, as well as in combination with bortezomib in patients with newly diagnosed multiple myeloma.METHODS: In this phase 3 trial, we randomly assigned 498 patients with relapsed or relapsed and refractory multiple myeloma to ...
Study To Evaluate Safety and Efficacy of P276-00 in Subjects With Refractory Multiple MyelomaStudy To Evaluate Safety and Efficacy of P276-00 in Subjects With Refractory Multiple Myeloma
The purpose of this study is to determine safety of P276-00 in patients with advanced multiple myeloma and whether P276-00 is effective in the treatment
Refractory Multiple Myeloma Global Clinical Trials Review, H2, 2014Refractory Multiple Myeloma Global Clinical Trials Review, H2, 2014
GlobalDatas clinical trial report, Refractory Multiple Myeloma Global Clinical Trials Review, H2, 2014 provides data on the Refractory Multiple Myeloma clinical trial scenario. This report
Association of Immune Marker Changes With Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma...Association of Immune Marker Changes With Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma...
TY - JOUR. T1 - Association of Immune Marker Changes With Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma. AU - Landgren, Ola. AU - Hofmann, Jonathan N.. AU - McShane, Charlene. AU - Santo, Loredana. AU - Korde, Neha AU - Hultcrantz, Malin. AU - Mailankody, Sham. AU - Kazandjian, Dickran. AU - Murata, Kazunori. AU - Thoren, Katie. AU - Ramanathan, Lakshmi. AU - Dogan, Ahmet. AU - Rustad, Even. AU - Lu, Sydney X.. AU - Akhlaghi, Theresia. AU - Kristinsson, Sigurdur Y.. AU - Björkholm, Magnus. AU - Devlin, Sean AU - Purdue, Mark P.. AU - Pfeiffer, Ruth M.. AU - Turesson, Ingemar. PY - 2019/7/18. Y1 - 2019/7/18. N2 - Importance Multiple myeloma is consistently preceded by monoclonal gammopathy of undetermined significance (MGUS). Risk models that estimate the risk of progression from MGUS to multiple myeloma use data from a single time point, usually the initial workup. Objective To longitudinally investigate the alterations of serum immune markers with stable ...
Systemic therapy of disseminated myeloma in passively immunized mice using measles virus-infected cell carriers<...Systemic therapy of disseminated myeloma in passively immunized mice using measles virus-infected cell carriers<...
TY - JOUR. T1 - Systemic therapy of disseminated myeloma in passively immunized mice using measles virus-infected cell carriers. AU - Liu, Chunsheng. AU - Russell, Stephen J.. AU - Peng, Kah Whye. PY - 2010/6. Y1 - 2010/6. N2 - Multiple myeloma (MM) is bone marrow plasma cell malignancy. A clinical trial utilizing intravenous administration of oncolytic measles virus (MV) encoding the human sodium-iodide symporter (MV-NIS) is ongoing in myeloma patients. However, intravenously administered MV-NIS is rapidly neutralized by antiviral antibodies. Because myeloma cell lines retain bone marrow tropism, they may be ideal as carriers for delivery of MV-NIS to myeloma deposits. A disseminated human myeloma (KAS 6/1) model was established. Biodistribution of MM1, a myeloma cell line, was determined after intravenous infusion. MM1 cells were found in the spine, femurs, and mandibles of tumor-bearing mice. Lethally irradiated MM1 cells remained susceptible to measles infection and transferred MV to KAS 6/1 ...
Association between non-malignant monoclonal gammopathy and adverse outcomes in chronic kidney disease: A cohort study |...Association between non-malignant monoclonal gammopathy and adverse outcomes in chronic kidney disease: A cohort study |...
1. Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Offord JR, et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med. 2006;354(13):1362-9. doi: 10.1056/NEJMoa054494 16571879. 2. Fermand JP, Bridoux F, Dispenzieri A, Jaccard A, Kyle RA, Leung N, et al. Monoclonal gammopathy of clinical significance: a novel concept with therapeutic implications. Blood. 2018;132(14):1478-85. doi: 10.1182/blood-2018-04-839480 30012636. 3. Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538-48. doi: 10.1016/S1470-2045(14)70442-5 25439696. 4. Leung N, Bridoux F, Hutchison CA, Nasr SH, Cockwell P, Fermand JP, et al. Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant. Blood. 2012;120(22):4292-5. doi: 10.1182/blood-2012-07-445304 23047823. 5. Kyle RA, Larson DR, Therneau TM, Dispenzieri A, ...
Multiple Myeloma: International Myeloma FoundationMultiple Myeloma: International Myeloma Foundation
The International Myeloma Foundation is dedicated to finding a cure for multiple myeloma through global research, and offers myeloma treatment guidelines and support.
Multiple Myeloma: International Myeloma FoundationMultiple Myeloma: International Myeloma Foundation
The International Myeloma Foundation is dedicated to finding a cure for multiple myeloma through global research, and offers myeloma treatment guidelines and support.
Prior autoimmune disease and risk of monoclonal gammopathy of undetermined significance and multiple myeloma: a systematic...Prior autoimmune disease and risk of monoclonal gammopathy of undetermined significance and multiple myeloma: a systematic...
BACKGROUND: Several observational studies have investigated autoimmune disease and subsequent risk of monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma. Findings have been largely inconsistent and hindered by the rarity and heterogeneity of the autoimmune disorders investigated. A systematic review of the literature was undertaken to evaluate the strength of the evidence linking prior autoimmune disease and risk of MGUS/multiple myeloma. METHODS: A broad search strategy using key terms for MGUS, multiple myeloma, and 50 autoimmune diseases was used to search four electronic databases (PubMed, Medline, Embase, and Web of Science) from inception through November 2011. RESULTS: A total of 52 studies met the inclusion criteria, of which 32 were suitably comparable to perform a meta-analysis. "Any autoimmune disorder" was associated with an increased risk of both MGUS [n = 760 patients; pooled relative risk (RR) 1.42; 95% confidence interval (CI), 1.14-1.75] and multiple ...
Induction of serum stimulation and plasma cell proliferation during chemotherapy of multiple myeloma | Blood | American Society...Induction of serum stimulation and plasma cell proliferation during chemotherapy of multiple myeloma | Blood | American Society...
Sequential sera from 45 patients with multiple myeloma (MM) and from 6 patients with solid tumors but normal bone marrows who received cyclophosphamide, 15 mg/kg/day for 4 days, were assayed for their effects on tritiated thymidine (3H-TdR) incorporation by normal bone marrow cells and malignant plasma cells. Pretreatment sera from 23 of the 45 patients with MM inhibited normal marrow cell proliferation relative to the effects of normal sera. Of these 45 sera, 30 inhibited plasma cell proliferation. This humoral inhibition was overcome by the induction of humoral stimulation at a predictable time during chemotherapy. The sera obtained sequentially from patients with MM and patients with normal bone marrows increased 3H-TdR uptake by both cell types by days 12-15 of therapy. Sequential changes in malignant marrow plasma cell 3H-TdR labeling indices paralleled the changes in serum activity, with an increased tumor cell growth fraction occurring at the time of peak serum stimulatory activity. The ...
Novel Therapeutics for Relapsed or Refractory Multiple Myeloma, Part 2 - The ASCO PostNovel Therapeutics for Relapsed or Refractory Multiple Myeloma, Part 2 - The ASCO Post
polyneuropathy (1 grade 3), edema (1 grade 3), and pyrexia (1 grade 1). No anti-AMG 420 antibodies were detected at doses up to 800 μg/d. Six patients had a complete response, 1 each at 6.5, 100, and 200 µg/d, and 3 at 400 µg/d; responses were ongoing for the past 3 months. There also were 2 partial remissions, a partial response at 50 µg/d, and a very good partial response at 800 µg/d. All 3 patients treated at 400 µg/d had an MRD-negative complete response.. Clinical Implications: AMG 420 showed evidence of clinical activity in patients with relapsed or refractory multiple myeloma. No major toxicities were observed up to 400 µg/d, and that is the recommended dose for further investigation; dose-limiting toxicities at 800 µg/d were cytokine-release syndrome and peripheral polyneuropathy. (Also, refer to Abstract 592, which highlights the activity of AMG 701, another anti-BCMA bispecific T-cell engager.4) The bispecific T-cell engager technology has already shown efficacy in leukemia and ...
Faculty Collaboration Database - Parameswaran Hari MDFaculty Collaboration Database - Parameswaran Hari MD
American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma. (Giralt S, Garderet L, Durie B, Cook G, Gahrton G, Bruno B, Hari P, Lokhorst H, McCarthy P, Krishnan A, Sonneveld P, Goldschmidt H, Jagannath S, Barlogie B, Mateos M, Gimsing P, Sezer O, Mikhael J, Lu J, Dimopoulos M, Mazumder A, Palumbo A, Abonour R, Anderson K, Attal M, Blade J, Bird J, Cavo M, Comenzo R, de la Rubia J, Einsele H, Garcia-Sanz R, Hillengass J, Holstein S, Johnsen HE, Joshua D, Koehne G, Kumar S, Kyle R, Leleu X, Lonial S, Ludwig H, Nahi H, Nooka A, Orlowski R, Rajkumar V, Reiman A, Richardson P, Riva E, San Miguel J, Turreson I, Usmani S, Vesole D, Bensinger W, Qazilbash M, Efebera Y, Mohty M, Gasparreto C, Gajewski J, LeMaistre CF, Bredeson C, Moreau P, Pasquini M, ...
International Myeloma Foundation - WikipediaInternational Myeloma Foundation - Wikipedia
The International Myeloma Foundation (IMF) is an American non-profit organization serving patients with myeloma, a cancer of plasma cells in the bone marrow. The IMF also provides support and information for family members, caregivers of myeloma patients, physicians and nurses. The organization is dedicated to improving the quality of life for all myeloma patients by focusing on four key areas: research, education, support, and advocacy. Founded in 1990 by Brian Novis, Susie Novis, and Brian G.M. Durie, M.D., IMF is a 501(c)3 resource for both patients and caregivers, offering programs that include educational seminars, a patient hotline, multilingual publications, government advocacy, and a web-based Personal Information Management system for recording care and treatment. The IMF is based in North Hollywood, California, and, according to its 2013 annual report, has a membership of 350,000 people in 140 countries. Its motto is "Improving lives - Finding the cure". The IMF was founded in 1990 by ...
Inhibiting the oncogenic translation program is an effective therapeutic strategy in multiple myeloma | Science Translational...Inhibiting the oncogenic translation program is an effective therapeutic strategy in multiple myeloma | Science Translational...
Multiple myeloma is a difficult-to-treat hematologic malignancy, where the MYC oncoprotein often plays a key role by stimulating ribosome production and up-regulating protein translation to satisfy the needs of rapidly proliferating cancer cells. By performing a high-throughput screen, Manier et al. determined that small-molecule rocaglate derivatives are active in multiple myeloma. The authors focused on one lead rocaglate derivative and showed that it reversed the effects of MYC, blocked excessive translation, induced tumor cell apoptosis, and decreased tumor cell proliferation. The treatment was safe and effective in multiple mouse models, suggesting rocaglates as potential therapeutic candidates for multiple myeloma. ...
Why it is crucial to assess response in multiple myeloma | VJHemOncWhy it is crucial to assess response in multiple myeloma | VJHemOnc
Carlos Fernandez de Larrea, MD, PhD from the Hospital Clínic de Barcelona, Barcelona, Spain gives an overview of his talk on response assessment in multiple myeloma (MM) held at the 2016 World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France. According to Dr de Larrea, the response assessment in MM is crucial. It is important to establish whether a patient has achieved complete remission (CR) and to identify patients who are relapsing or progressing after different lines of treatment. Dr de Larrea further discusses the various techniques used to assess response, such as electrophoresis in serum and urine and imaging techniques. Recorded at the 2016 World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France.
Multiple myeloma | Kaiser PermanenteMultiple myeloma | Kaiser Permanente
Multiple myeloma (plasma cell neoplasm) is a rare type of cancer that results in the uncontrolled production of one type of white blood cell (plasma cell) in the bone marrow. The cancer cells can crowd out normal blood cells, causing a reduction in red blood cells (anemia). The overproduction of plasma cells causes an...
Haematopoietic stem cell mobilization with plerixafor and G-CSF in patients with multiple myeloma transplanted with autologous...Haematopoietic stem cell mobilization with plerixafor and G-CSF in patients with multiple myeloma transplanted with autologous...
TY - JOUR. T1 - Haematopoietic stem cell mobilization with plerixafor and G-CSF in patients with multiple myeloma transplanted with autologous stem cells. AU - Basak, Grzegorz W.. AU - Jaksic, Ozren. AU - Koristek, Zdenek. AU - Mikala, Gabor. AU - Basic-Kinda, Sandra. AU - Mayer, Jiri. AU - Masszi, Tamas. AU - Giebel, Sebastian. AU - Labar, Boris. AU - Wiktor-Jedrzejczak, Wieslaw. PY - 2011/6/1. Y1 - 2011/6/1. N2 - A proportion of patients with multiple myeloma (MM) who have already undergone autologous stem cell transplantation (autoSCT) might benefit from a further transplantation. For this, they might need to undergo another round of stem cell mobilization. We analyzed retrospectively the outcomes of stem cell mobilization with plerixafor and granulocyte colony-stimulating factor (G-CSF) in a group of 30 patients who had undergone autoSCT previously, and in 46 other patients. The previously transplanted patients were significantly different from the remaining patients with respect to the ...
Leukemia and Lymphoma Society | | Multiple Myeloma BlogLeukemia and Lymphoma Society | | Multiple Myeloma Blog
I dont know about you, but I am fielding more and more questions from multiple myeloma patients and caregivers about where to find financial assistance.Here is a link to a site/organization I havent tried called Patient Advocate Foundation Co-Pay Relief:Patient Advocate Foundations Co-Pay Relief (CPR) for Multiple Myeloma Patients.I have personally been aproved by the. ...
99m</sup>Tc-MIBI whole body scintigraphy and P-glycoprotein for the prediction of multiple drug resistance in multiple myeloma...99m</sup>Tc-MIBI whole body scintigraphy and P-glycoprotein for the prediction of multiple drug resistance in multiple myeloma...
TY - JOUR. T1 - 99mTc-MIBI whole body scintigraphy and P-glycoprotein for the prediction of multiple drug resistance in multiple myeloma patients. AU - Fallahi, Babak. AU - Beiki, Davood. AU - Mousavi, Seyed Asadollah. AU - Gholamrezanezhad, Ali. AU - Eftekhari, Mohammad. AU - Fard-Esfahani, Armaghan. AU - Alimoghaddam, Kamran. AU - Mirpour, Sahar. AU - Eskandarian, Alireza. AU - Saghari, Mohsen. PY - 2009/9/1. Y1 - 2009/9/1. N2 - Multi-drug resistance (MDR) is a major challenge in the treatment of multiple myeloma (MM). There is low sensitivity of technetium-99m methoxy isobutyl isonitrile (99mTc-MIBI) whole body scan (WBS) in the detection of active MM lesions, because 99Tc-MIBI is washed out from malignant cells in the presence of P-glycoprotein (PGP). The objective of the present cohort study was to evaluate of 99mTc-MIBI WBS in the prediction of MDR in MM patients during a course of one year follow up. Thirty four patients with MM (25 male, 9 female of mean age 54.12±11.46 years) entered ...
Treatment of Myeloma Bone Disease - PDFTreatment of Myeloma Bone Disease - PDF
Treatment of Myeloma Bone Disease James R. Berenson, MD Medical & Scientific Director Institute for Bone Cancer & Myeloma Research West Hollywood, CA Clinical Consequences of Myeloma Bone Disease Pathological
Blog Archives - Multiple Myeloma - Survival Rate Statistics by HospitalBlog Archives - Multiple Myeloma - Survival Rate Statistics by Hospital
However this time I am more apprehensive of the new MRD test. All the current tests for light chains, lesions, bone marrow biopsy, M spike, etc. have always indicated that I was in CR. The MRD test is a far more sensitive test, and will be able to see if there are any myeloma cells left in my system. So a MRD negative result would confirm that my disease is under control based on the most sensitive tests yet available for multiple myeloma diagnostics. And a positive result would just SUCK. Other diseases use a MRD test to determine if a patients treatment has been successful, and when or if it should be changed. MRD is used for acute lymphoblastic leukemia (ALL), and MRD status is one of the most powerful predictors of disease-free and overall survival for children with ALL. The promise for myeloma is that we are able to use this test in the same manner. The International Myeloma Foundation has developed a program called the Black Swan Initiative intended to use a test for MRD with enough ...
Relapse of multiple myeloma presenting as lower lip numbness<...Relapse of multiple myeloma presenting as lower lip numbness<...
TY - JOUR. T1 - Relapse of multiple myeloma presenting as lower lip numbness. AU - Al-Riyami, Yusra M.. AU - Bakathir, Abdulaziz. AU - Al-Farsi, Khalil. AU - Al-Azri, Faisal. PY - 2016/11/1. Y1 - 2016/11/1. N2 - Multiple myeloma (MM) is an uncommon malignancy characterised by the proliferation of clonal plasma cells. There are few published reports describing the extramedullary presentation of MM manifesting primarily in the head and neck region. In addition, the occurrence of an isolated relapse of MM in these sites is exceedingly rare. We report a 56-year-old female who presented to the Sultan Qaboos University Hospital, Muscat, Oman, in 2010 with sudden-onset numbness of the lower lip. She had a history of MM in remission following chemotherapy and a bone marrow transplant. Clinical and radiographic examinations were indicative of a possible relapse of MM, which was subsequently confirmed by bone marrow aspiration and histopathological evaluation. This unique case highlights the unusual site ...
High-frequency promoter hypermethylation of the deleted in liver cancer-1 gene in multiple myeloma | Journal of Clinical...High-frequency promoter hypermethylation of the deleted in liver cancer-1 gene in multiple myeloma | Journal of Clinical...
Background: Deleted in liver cancer-1 (DLC-1) is a tumour suppressor gene that is inactive in liver carcinogenesis. It encodes a ρ-guanosine triphosphatase-activating protein (ρ-GAP) and maps to one of the deleted regions (8p21.3-22). Little is known, however, about the methylation status of the DLC-1 promoter in myeloma cells.. Aim: To identify whether methylation of DLC-1 was associated in pathogenesis of multiple myeloma.. Methods: Reverse transcription-polymerase chain reaction (RT-PCR) was used to detect DLC-1 transcripts in RPMI 8226, U266, OPM-2 and XG-2 cell lines. The methylation status was determined by methylation-specific PCR followed by bisulphite DNA sequencing in these four cell lines and in the bone marrow of 14 patients with multiple myeloma and 4 normal patients. DLC-1 mRNA expression in cells with or without treatment with 5-aza-deoxycytidine (5-aza-CdR) or trichostatin A (TSA) was investigated by real-time RT-PCR.. Results: RPMI 8226 and U266 showed complete methylation and ...
Clinical Decision Making in Multiple Myeloma for the Transplant-Eligible Patient-Upfront Transplant Versus Maintenance Therapy ...Clinical Decision Making in Multiple Myeloma for the Transplant-Eligible Patient-Upfront Transplant Versus Maintenance Therapy ...
The Role of High Dose Chemotherapy With Autologous Stem Cell Rescue in Multiple Myeloma in the Era of Conventional Cytotoxic Chemotherapy. Before the introduction of proteasome inhibitors (PIs) and immunomodulatory agents (IMiDs), high dose melphalan with ASCT following induction therapy was considered the standard approach for transplant-eligible patients with newly diagnosed MM. The first randomized controlled trial from the Intergroupe Francais du Myelome (IFM90), published in 1996, randomized newly diagnosed MM patients to an older chemotherapy regimen (vincristine/carmustine, cyclophosphamide, prednisone alternating with carmustine, vincristine, adriamycin, prednisone; VMCP/BVAP) for 12 cycles versus 4 to 6 cycles of VMCP/BVAP followed by high dose therapy with autologous bone marrow transplant.1 Those patients randomized to the transplant arm compared with the high dose chemotherapy arm had a superior 5-year event-free survival (EFS) (28% versus 10%, respectively, P = .01) and OS (52% ...
Maintenance Therapy with Immunomodulatory Drugs after Autologous Stem Cell Transplantation in Patients with Multiple Myeloma: A...Maintenance Therapy with Immunomodulatory Drugs after Autologous Stem Cell Transplantation in Patients with Multiple Myeloma: A...
Maintenance Therapy with Immunomodulatory Drugs after Autologous Stem Cell Transplantation in Patients with Multiple Myeloma: A Meta-Analysis of Randomized Controlled Trials. . Biblioteca virtual para leer y descargar libros, documentos, trabajos y tesis universitarias en PDF. Material universiario, documentación y tareas realizadas por universitarios en nuestra biblioteca. Para descargar gratis y para leer online.
Assessment of whole body MRI and sestamibi technetium-99m bone marrow scan in prediction of multiple myeloma disease...Assessment of whole body MRI and sestamibi technetium-99m bone marrow scan in prediction of multiple myeloma disease...
Assessment of whole body MRI and sestamibi technetium-99m bone marrow scan in prediction of multiple myeloma disease progression and outcome: a prospective comparative study Journal Articles Refereed ...
Evaluation of a Cooperative Group Human Myeloma Protocol Using the MOPC 104E Myeloma ModelEvaluation of a Cooperative Group Human Myeloma Protocol Using the MOPC 104E Myeloma Model
Data are presented on the response rates, maximum rate of cell kill, and survival rates for individual and groups of mice with MOPC 104E myeloma treated with a variety of chemotherapeutic agents and combination regimens used in clinical human myeloma. The tumor immunoglobulin M measurements are used to evaluate the therapeutic effects of drugs. Prednisolone and mescaline, when given as single drugs, showed no therapeutic action and the animals died of tumor as in the controls. The immunoglobulin M values are very similar and ranged between 8, 125 and 13, 410 μg/mouse. Prednisolone and melphalan given in combination indicated therapeutic effect. 1, 3-Bis(2-chloroethyl)-1-nitrosourea-cyclophosphamide-prednisolone combination caused tumor regression but was toxic as shown by the immunoglobulin M values and percentage of survival. The complications and potential uses of this system, which utilized only 40 animals in 64 days, are discussed. © 1975, American Association for Cancer Research. All ...
Retrospective review of multiple myeloma and immunosecretory disorder cases diagnosed in a tertiary settingRetrospective review of multiple myeloma and immunosecretory disorder cases diagnosed in a tertiary setting
SUMMARY OF RESULTS: In total, 582 patients were included - 39 patients had multiple myeloma (6.7%). A single case of plasmacytoma and plasma cell leukaemia was identified. Waldenströms macroglobulinaemia was identified in seven patients (1.2%) and monoclonal gammopathy of undetermined significance (MGUS) in 83 patients (14.3%). Due to the risk of progression from MGUS to multiple myeloma, patients need to be re-evaluated biannually, shown to be the case in only 11% of cases ...
Glycosphingolipid synthesis inhibition limits osteoclast activation and myeloma bone disease. - Department of PaediatricsGlycosphingolipid synthesis inhibition limits osteoclast activation and myeloma bone disease. - Department of Paediatrics
Glycosphingolipids (GSLs) are essential constituents of cell membranes and lipid rafts and can modulate signal transduction events. The contribution of GSLs in osteoclast (OC) activation and osteolytic bone diseases in malignancies such as the plasma cell dyscrasia multiple myeloma (MM) is not known. Here, we tested the hypothesis that pathological activation of OCs in MM requires de novo GSL synthesis and is further enhanced by myeloma cell-derived GSLs. Glucosylceramide synthase (GCS) inhibitors, including the clinically approved agent N-butyl-deoxynojirimycin (NB-DNJ), prevented OC development and activation by disrupting RANKL-induced localization of TRAF6 and c-SRC into lipid rafts and preventing nuclear accumulation of transcriptional activator NFATc1. GM3 was the prevailing GSL produced by patient-derived myeloma cells and MM cell lines, and exogenous addition of GM3 synergistically enhanced the ability of the pro-osteoclastogenic factors RANKL and insulin-like growth factor 1 (IGF-1) to induce
Significance of Oligoclonal Bands after Stem Cell Transplantation in Multiple Myeloma CasesSignificance of Oligoclonal Bands after Stem Cell Transplantation in Multiple Myeloma Cases
Objective: To determine the characteristics of oligoclonal bands that are frequently detected by serum proteinelectrophoresis (SPEP) and immunofixation electrophoresis (IFE) after stem cell transplantation. Methods: Weretrospectively analyzed 56 patients with multiple myeloma (MM) undergoing transplantation, and standardimmunofixation electrophoresis was used to identify and quantify paraproteins. Results: The median follow-upwas 35 months (range, 10-76months) and 21 patients relapsed. Twelve (25.0%) demonstrated oligoclonal bandsafter a median time 1.4 months (range, 1-3months), with a median duration of 5.8 months (range, 1-15months).The majority patients with oligoclonal bands had normal quantities of immunoglobulins and the one year eventfree survival (EFS) was 92%, even higher than for patients without OBs (P=0.002). Conclusion: Oligoclonalbands frequent develop post-transplantation in MM cases. In the vast majority of patients, they may notrepresent relapsed disease, and more likely represent a
Clinical Implication of Bone Marrow Perfusion Patterns Imaged by Dynamic MRI in Multiple MyelomaClinical Implication of Bone Marrow Perfusion Patterns Imaged by Dynamic MRI in Multiple Myeloma
Background: Multiple myeloma (MM) is a clonal plasma cell neoplasm characterized by proliferation of neoplastic plasma cells in bone marrow (BM). So fa
PancytopeniaPancytopenia
ChemotherapyChemotherapy
Marine Corps Base Camp LejeuneMarine Corps Base Camp Lejeune
Nephrotic syndromeNephrotic syndrome
Priority reviewPriority review
Development of analogs of thalidomideDevelopment of analogs of thalidomide
Charles Freeman GeschickterCharles Freeman Geschickter
Dana-Farber Cancer InstituteDana-Farber Cancer Institute
PrognosisPrognosis
Alcohol and cancerAlcohol and cancer
Mangum Mound SiteMangum Mound Site
Otto KahlerOtto Kahler
Kenneth C. Anderson (physician)Kenneth C. Anderson (physician)
Avery LipmanAvery Lipman
Hematological Cancer Research Investment and Education ActHematological Cancer Research Investment and Education Act
Steven T. RosenSteven T. Rosen
Judith MeuliJudith Meuli
Robert Ira LewyRobert Ira Lewy
AA amyloidosisAA amyloidosis
George CasellaGeorge Casella
Cyclin D1Cyclin D1
Immunomodulatory imide drugImmunomodulatory imide drug
Stacy RobinsonStacy Robinson
Gilbert Wheeler BeebeGilbert Wheeler Beebe
Cancer stem cellCancer stem cell
SyndecanSyndecan
William MacIntyreWilliam MacIntyre
BloodwiseBloodwise
Tumour heterogeneityTumour heterogeneity
DysfibrinogenemiaDysfibrinogenemia
Plasma cellPlasma cell
T细胞 - 维基百科，自由的百科全书T细胞 - 维基百科，自由的百科全书
Hematopoietic stem cell transplantationHematopoietic stem cell transplantation
Tüvirakud - Vikipeedia, vaba entsüklopeediaTüvirakud - Vikipeedia, vaba entsüklopeedia
NephrologyNephrology
Category:Cancer - Simple English Wikipedia, the free encyclopediaCategory:Cancer - Simple English Wikipedia, the free encyclopedia
Mosaic (genetics)Mosaic (genetics)
Pelger-Huet anomalyPelger-Huet anomaly
ProteasomeProteasome
LIG3, a enciclopedia libreLIG3, a enciclopedia libre
Ալերգիա - Վիքիպեդիա՝ ազատ հանրագիտարանԱլերգիա - Վիքիպեդիա՝ ազատ հանրագիտարան
Antibody-dependent cellular cytotoxicityAntibody-dependent cellular cytotoxicity
Minimal residual diseaseMinimal residual disease
Immunoglobulin EImmunoglobulin E
Monosomy 9pMonosomy 9p
Jacobsen syndromeJacobsen syndrome
Hair coloringHair coloring
Acute lymphoblastic leukemiaAcute lymphoblastic leukemia
Primary myelofibrosisPrimary myelofibrosis
Peliosis hepatisPeliosis hepatis
Gel electrophoresis of proteinsGel electrophoresis of proteins
Causes of cancer painCauses of cancer pain
AstraZenecaAstraZeneca
Lista de revistas científicas de medicina - Wikipédia, a enciclopédia livreLista de revistas científicas de medicina - Wikipédia, a enciclopédia livre
Birth defectBirth defect
AntibodyAntibody
CyclophosphamideCyclophosphamide
AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPhenomena and ProcessesInformation ScienceHealth Care
Multiple MyelomaMyeloma ProteinsBoronic AcidsPyrazinesThalidomidePlasma CellsMelphalanParaproteinemiasMonoclonal Gammopathy of Undetermined SignificanceLeukemia, Plasma CellPlasmacytomaDexamethasoneTransplantation, AutologousSyndecan-1Bone MarrowAntineoplastic AgentsCell Line, TumorBence Jones ProteinParaproteinsImmunoglobulin Light ChainsAntineoplastic Combined Chemotherapy ProtocolsProteasome InhibitorsHematopoietic Stem Cell TransplantationOsteolysisBone DiseasesInterleukin-6Waldenstrom MacroglobulinemiaApoptosisChromosomes, Human, Pair 14Tumor Cells, CulturedMice, SCIDBone Marrow CellsImmunoglobulin kappa-ChainsDiphosphonatesVincristineSyndecansPrednisonePrognosisMaintenance ChemotherapyTreatment OutcomeImmunoglobulin lambda-ChainsAntineoplastic Agents, AlkylatingRemission InductionStem Cell TransplantationDrug Resistance, NeoplasmTranslocation, GeneticDoxorubicinGene Expression Regulation, NeoplasticCombined Modality TherapyRecurrenceSurvival AnalysisSurvival RateCyclophosphamideProtease InhibitorsStromal CellsChromosomes, Human, Pair 13Cell ProliferationHypergammaglobulinemiabeta 2-MicroglobulinAmyloidosisDisease-Free SurvivalFlow CytometryBone Marrow ExaminationSalvage TherapyDisease ProgressionCell SurvivalReceptors, Interleukin-6Chromosomes, Human, Pair 4Immunologic FactorsReceptor, Fibroblast Growth Factor, Type 3In Situ Hybridization, FluorescenceImmunoglobulin DNeoplasm ProteinsNeoplasms, Plasma CellDrug SynergismChromosome AberrationsOsteoclastsAntibodies, MonoclonalXenograft Model Antitumor AssaysImmunoglobulinsHematopoietic Stem Cell MobilizationPeripheral Blood Stem Cell TransplantationTransplantation ConditioningSignal TransductionAngiogenesis InhibitorsLymphomaImmunoglobulin AHematologic NeoplasmsB-LymphocytesOsteonecrosisInduction ChemotherapyRetrospective StudiesTime FactorsCell DivisionOxides
What is end stage multiple myeloma? | Reference.comWhat is end stage multiple myeloma? | Reference.com
Multiple Myeloma Diagnosis, Causes, Definition, Symptoms, StagesMultiple Myeloma Diagnosis, Causes, Definition, Symptoms, Stages
FDA Approves Celgenes Pomalyst For Advanced Multiple Myeloma - Quick FactsFDA Approves Celgene's Pomalyst For Advanced Multiple Myeloma - Quick Facts
Recurrent Multiple MyelomaRecurrent Multiple Myeloma
Multiple Myeloma Research Foundation, UM Form Multiple Myeloma Sequencing Initiative | GenomeWebMultiple Myeloma Research Foundation, UM Form Multiple Myeloma Sequencing Initiative | GenomeWeb
2017-03: A Single-Arm, Open-label Study of Anti-Signaling Lymphocytic Activation Molecule F7 (Anti-SLAMF7) Monoclonal Antibody ...2017-03: A Single-Arm, Open-label Study of Anti-Signaling Lymphocytic Activation Molecule F7 (Anti-SLAMF7) Monoclonal Antibody ...
Multiple myeloma | The BMJMultiple myeloma | The BMJ
Multiple myeloma: MedlinePlus GeneticsMultiple myeloma: MedlinePlus Genetics
Multiple Myeloma | Encyclopedia.comMultiple Myeloma | Encyclopedia.com
Types of Multiple MyelomaTypes of Multiple Myeloma
Radiation Therapy for Multiple MyelomaRadiation Therapy for Multiple Myeloma
Multiple Myeloma SymptomsMultiple Myeloma Symptoms
Multiple Myeloma | NovartisMultiple Myeloma | Novartis
Anthropometry and multiple myeloma. - PubMed - NCBIAnthropometry and multiple myeloma. - PubMed - NCBI
Multiple Myeloma: Symptoms, Signs, Causes & TreatmentMultiple Myeloma: Symptoms, Signs, Causes & Treatment
Multiple Myeloma: Symptoms & Types (Medically Reviewed)Multiple Myeloma: Symptoms & Types (Medically Reviewed)
Signs and Symptoms of Multiple MyelomaSigns and Symptoms of Multiple Myeloma
Multiple myeloma: Symptoms, causes, and treatmentMultiple myeloma: Symptoms, causes, and treatment
Risk Factor: Multiple MyelomaRisk Factor: Multiple Myeloma
What is Multiple Myeloma?What is Multiple Myeloma?
Multiple Myeloma Differential DiagnosesMultiple Myeloma Differential Diagnoses
Cellular Immunotherapy for Multiple Myeloma Advancing RapidlyCellular Immunotherapy for Multiple Myeloma Advancing Rapidly
Multiple Myeloma March - Myeloma CanadaMultiple Myeloma March - Myeloma Canada
Multiple Myeloma, Cancer, Information, ResourcesMultiple Myeloma, Cancer, Information, Resources
Hyperphosphatemia in multiple myeloma | SpringerLinkHyperphosphatemia in multiple myeloma | SpringerLink
Multiple Myeloma | OncoLinkMultiple Myeloma | OncoLink
Multiple myeloma - Symptoms and causes - Mayo ClinicMultiple myeloma - Symptoms and causes - Mayo Clinic
Multiple myeloma: link to gene involved in agingMultiple myeloma: link to gene involved in aging
Pathophysiology of Bone Disease in Multiple Myeloma | SpringerLinkPathophysiology of Bone Disease in Multiple Myeloma | SpringerLink
How to Diagnose Multiple Myeloma (with Pictures) - wikiHowHow to Diagnose Multiple Myeloma (with Pictures) - wikiHow
NCCN Guidelines for Patients® | Multiple MyelomaNCCN Guidelines for Patients® | Multiple Myeloma
Immunological Dysregulation in Multiple Myeloma MicroenvironmentImmunological Dysregulation in Multiple Myeloma Microenvironment
NCCN Guidelines for Patients® | Multiple MyelomaNCCN Guidelines for Patients® | Multiple Myeloma
AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPhenomena and ProcessesInformation ScienceHealth Care
Multiple MyelomaMyeloma ProteinsBoronic AcidsPyrazinesThalidomidePlasma CellsMelphalanParaproteinemiasMonoclonal Gammopathy of Undetermined SignificanceLeukemia, Plasma CellPlasmacytomaDexamethasoneTransplantation, AutologousSyndecan-1Bone MarrowAntineoplastic AgentsCell Line, TumorBence Jones ProteinParaproteinsImmunoglobulin Light ChainsAntineoplastic Combined Chemotherapy ProtocolsProteasome InhibitorsHematopoietic Stem Cell TransplantationOsteolysisBone DiseasesInterleukin-6Waldenstrom MacroglobulinemiaApoptosisChromosomes, Human, Pair 14Tumor Cells, CulturedMice, SCIDBone Marrow CellsImmunoglobulin kappa-ChainsDiphosphonatesVincristineSyndecansPrednisonePrognosisMaintenance ChemotherapyTreatment OutcomeImmunoglobulin lambda-ChainsAntineoplastic Agents, AlkylatingRemission InductionStem Cell TransplantationDrug Resistance, NeoplasmTranslocation, GeneticDoxorubicinGene Expression Regulation, NeoplasticCombined Modality TherapyRecurrenceSurvival AnalysisSurvival RateCyclophosphamideProtease InhibitorsStromal CellsChromosomes, Human, Pair 13Cell ProliferationHypergammaglobulinemiabeta 2-MicroglobulinAmyloidosisDisease-Free SurvivalFlow CytometryBone Marrow ExaminationSalvage TherapyDisease ProgressionCell SurvivalReceptors, Interleukin-6Chromosomes, Human, Pair 4Immunologic FactorsReceptor, Fibroblast Growth Factor, Type 3In Situ Hybridization, FluorescenceImmunoglobulin DNeoplasm ProteinsNeoplasms, Plasma CellDrug SynergismChromosome AberrationsOsteoclastsAntibodies, MonoclonalXenograft Model Antitumor AssaysImmunoglobulinsHematopoietic Stem Cell MobilizationPeripheral Blood Stem Cell TransplantationTransplantation ConditioningSignal TransductionAngiogenesis InhibitorsLymphomaImmunoglobulin AHematologic NeoplasmsB-LymphocytesOsteonecrosisInduction ChemotherapyRetrospective StudiesTime FactorsCell DivisionOxides
BoneSurvivalDexamethasoneCancer2017DaratumumabTumorAutologousMonoclonalMayo ClinicNewlyHigh-risk multiple myelomaTumorsStages of multiple myelomaAssessment in Multiple MyelomaStage II or III multiple myelomaMGUSHuman Multiple MyelomaAbnormalDiagnosis of multiple myelomaAntibodies2016Cure for multiple myelomaTreatmentsPlasmacytomaCauses multiple myelomaLesionsProteinsInternational Myeloma Working GroupCancerNewly diagnosedPlasmacytomasLymphomaRelapsePlasma cellsCause of multiple myelomaIncidence of multiple myelomaIndividuals with multiple myelomaDiseaseIncurableDevelop multiple myelomaPeople with myelomaLevels in multiple myeloma patientsSymptoms of multiple myeloma includeEffectively kill multiple myeloma cellsPatients with relapsed refractory multiple myelomaCellsPathogenesisBone marrowAnti-myelomaRefractory myelomaRelapsed and refractory multiple myelomaRisk factors for multiple myelomaTreatment regimens for multiple myelomaAdvanced multiple myeloma basedAssessed multiple myeloma patientsLeukemiaTherapyBlood
Bone25
Survival4
Dexamethasone2
Cancer7
  • According to the American Cancer Society, there are three stages of multiple myeloma. (reference.com)
  • Because plasma cells are part of the immune system and produce antibodies (disease-fighting proteins), the development of myeloma results in an impaired immune system with problems associated with an unbalanced antibody response, as well as other problems as associated with other types of cancer , including pain and weakness. (emedicinehealth.com)
  • Multiple myeloma is a cancer of the plasma cells. (mayo.edu)
  • The American Cancer Society estimates 20,000 people are diagnosed with multiple myeloma in the U.S. each year. (mayo.edu)
  • Stage II or III multiple myeloma is characterized by an intermediate or high amount of cancer in the body. (lacancernetwork.com)
  • A team of Mayo Clinic Cancer Center scientists has been awarded a Specialized Program of Research Excellence (SPORE) grant in multiple myeloma from the National Cancer Institute . (mayocliniclabs.com)
  • The Mayo Clinic Cancer Center is one of only three cancer centers to receive a SPORE grant for multiple myeloma cancer research. (mayocliniclabs.com)
20171
  • 2017. "Whole-body MRI, Dynamic Contrast-enhanced MRI, and Diffusion-weighted Imaging for the Staging of Multiple Myeloma. (ugent.be)
Daratumumab1
Tumor2
Autologous1
Monoclonal5
Mayo Clinic4
Newly1
High-risk multiple myeloma1
  • Therefore, new strategies especially for relapsed and refractory and high-risk multiple myeloma (RRMM, HRMM) patients, who have poor response to current therapies, are required. (utupub.fi)
Tumors1
Stages of multiple myeloma2
  • During the early stages of multiple myeloma, no symptoms may be apparent. (reference.com)
  • What are the stages of multiple myeloma? (reference.com)
Assessment in Multiple Myeloma1
  • It reviews the diagnostic performance, prognostic value, and role in therapy assessment in multiple myeloma and its precursor stages. (ugent.be)
Stage II or III multiple myeloma1
MGUS1
  • People with MGUS do not have symptoms associated with multiple myeloma. (mayo.edu)
Human Multiple Myeloma2
  • J. Abdi, J. Garssen and F. Redegeld, "Toll-Like Receptors in Human Multiple Myeloma: New Insight into Inflammation-Related Pathogenesis", Current Molecular Medicine (2014) 14: 423. (eurekaselect.com)
  • To investigate the patterns of genetic lesions in a panel of 23 human multiple myeloma cell lines (HMCLs), we made a genomic integrative analysis involving FISH, and both gene expression and genome-wide profiling approaches. (unimi.it)
Abnormal1
Diagnosis of multiple myeloma5
Antibodies16
20162
  • In 2016, Myeloma Canada produced two patient submissions to pCODR for daratumumab, in combination with dexamethasone, and one for ixazomib plus lenalidomide (Revlimid®) and dexamethasone. (newswire.ca)
  • In 2016, the American Cancer Society estimates that 30,330 new multiple myeloma cases will be diagnosed and 12,650 cancer deaths due to multiple myeloma would occur. (cancerquest.org)
Cure for multiple myeloma5
Treatments22
Plasmacytoma8
Causes multiple myeloma1
Lesions13
  • About 70% of individuals with multiple myeloma have soft spots or lesions in their bones. (encyclopedia.com)
  • Multiple myeloma (MM) is a malignancy of plasma cells characterized by growth in the bone marrow (BM) environment and the development of lytic lesions in the skeleton. (springer.com)
  • Multiple myeloma can cause soft spots in the bone called osteolytic lesions, which appear as holes on an X-ray . (healthline.com)
  • Radiologically, multiple destructive lytic lesions of the skeleton, as well as severe demineralization, characterize multiple myeloma. (medscape.com)
  • Although the osseous structures may appear radiographically normal or simply osteopenic, the classic appearance is of multiple, discrete, small, lytic lesions. (medscape.com)
  • A bone scan may show which bones are involved with multiple myeloma, but often the lesions cannot be seen. (aaos.org)
  • These x-rays show typical lesions caused by multiple myeloma. (aaos.org)
  • A mnemonic sometimes used to remember some of the common symptoms of multiple myeloma is CRAB: C = calcium (elevated), R = renal failure, A = anemia, B = bone lesions. (wikipedia.org)
  • On admission, initial NECT of the abdomen and pelvis demonstrated multiple osteolytic lesions in the pelvis, right femur, and lumbar spine with associated soft-tissue component and mass effect compromising the spinal canal at L1 (Figure 1). (appliedradiology.com)
  • MRI of the lumbar spine demonstrated multiple, multilevel T1 and T2 hypointense lesions and pathologic compression fracture with posterior expansile mass at L1 causing severe spinal and neural foraminal stenosis (Figure 2). (appliedradiology.com)
  • Subsequent myeloma work-up with a radiographic bone survey redemonstrated multiple osteolytic lesions throughout the lumbar spine, pelvis, and bilateral proximal femurs (Figure 4). (appliedradiology.com)
  • On imaging, multiple myeloma is hallmarked by focal or diffuse marrow infiltration and well-circumscribed osteolytic lesions. (appliedradiology.com)
  • Skeletal radiographs are important in staging multiple myeloma and revealing lytic lesions, vertebral compression fractures, and osteoporosis. (aafp.org)
Proteins12
International Myeloma Working Group3
  • The International Myeloma Working Group (IMWG) was formed by the IMF to encourage dialog and collaboration among the world's leading myeloma experts. (myeloma.org)
  • A focal lytic lesion must be 5 mm or greater in size to be considered a true abnormality by the latest International Myeloma Working Group (IMWG) criteria. (medscape.com)
  • Dimopoulos et al (writing for the International Myeloma Working Group) reviewed the literature of all imaging modalities used in multiple myeloma and provided recommendations for each modality. (medscape.com)
Cancer70
  • Multiple myeloma is the second most common (10-15% of all) haematological cancer. (bmj.com)
  • Although myeloma remains an incurable cancer, survival is improving, and newly diagnosed patients are now projected to live for around five years. (bmj.com)
  • Multiple myeloma is a cancer in which antibody-producing plasma cells grow in an uncontrolled and invasive (malignant) manner. (encyclopedia.com)
  • Multiple myeloma , also known as plasma cell myeloma, is the second-most common cancer of the blood. (encyclopedia.com)
  • Multiple myeloma accounts for approximately 1% of all cancers and 2% of all deaths from cancer. (encyclopedia.com)
  • Multiple myeloma is one of the leading causes of cancer deaths among African Americans . (encyclopedia.com)
  • 3 After initial therapy, it is common for individuals with multiple myeloma to become less responsive to therapy or eventually experience a relapse, when the cancer returns. (novartis.com)
  • Multiple myeloma is a cancer that forms in a type of white blood cell called a plasma cell. (mayoclinic.org)
  • Multiple myeloma causes cancer cells to accumulate in the bone marrow, where they crowd out healthy blood cells. (mayoclinic.org)
  • Multiple myeloma is a cancer of certain cells of the bone marrow called plasma cells. (medicinenet.com)
  • Multiple myeloma is a form of bone marrow cancer . (medicinenet.com)
  • The American Cancer Society (ACS) estimates the risk of developing multiple myeloma over a lifetime as 1 in 143 or 0.7 percent . (medicalnewstoday.com)
  • Multiple myeloma is a type of cancer. (medicalnewstoday.com)
  • The signs and symptoms of multiple myeloma depend on the stage of the cancer and the general health of the patient. (medicalnewstoday.com)
  • Multiple myeloma is not usually curable and treatment is therefore aimed at delaying the progression of the cancer for as long as possible. (news-medical.net)
  • Cancer Care provides free, professional support services for people affected by multiple myeloma, as well as multiple myeloma treatment information and additional resources. (cancercare.org)
  • Savage D, Garrett TJ (1986) Multiple myeloma masquerading as metastatic breast cancer. (springer.com)
  • Multiple myeloma is a cancer of the blood (hematologic cancer) in which one population of clonal (identical) plasma cells starts to reproduce uncontrollably. (oncolink.org)
  • Scientists from The Institute of Cancer Research in the UK found a genetic variant called TERC among four new variants that they linked to multiple myeloma - a form of cancer that affects immune cells produced in the bone marrow for circulation in the blood. (medicalnewstoday.com)
  • Myeloma is a relatively uncommon cancer according to the American Cancer Society statistics, with a 1 in 149 risk of developing the disease in the US. (medicalnewstoday.com)
  • For the study, the research team analyzed the genetic make-up of 4,692 patients who had myeloma, and compared this with DNA of 10,990 people who did not have the blood cancer. (medicalnewstoday.com)
  • Richard Houlston, professor of molecular and population genetics at The Institute of Cancer Research ( ICR ), explains: "Our study has taken an important step forward in understanding the genetics of myeloma, and suggested an intriguing potential link with a gene that acts as a cell's internal timer. (medicalnewstoday.com)
  • If the cancer has spread, see Guide 1 on page 16 for recommended testing to assess the severity of multiple myeloma and its symptoms. (nccn.org)
  • Next steps  If tests show the cancer has spread, the next treatment options depend on the severity of myeloma and its symptoms. (nccn.org)
  • According to Stanford University, multiple myeloma is rare, accounting for only 1 percent of all cancer cases in the United States. (healthline.com)
  • Among the many frustrating things about the blood cancer known as multiple myeloma is the fact that it's hard to predict who will get it. (healthcentral.com)
  • But multiple myeloma cancer cells are often found to have an extra chromosome or may be missing a part of one chromosome. (healthcentral.com)
  • Reuters) - Amgen Inc's Kyprolis drug failed to extend survival compared to standard care in a trial involving patients with advanced multiple myeloma, a type of blood cancer that develops in the bone marrow. (yahoo.com)
  • The physicians and researchers in the Malignant Hematology Program at Moffitt Cancer Center are working to develop new and better multiple myeloma screening techniques in order to detect and address the condition as early as possible. (moffitt.org)
  • According to the American Cancer Society, in 2015 about 26,850 people will be diagnosed with multiple myeloma (14,090 men and 12,760 women). (nurse.com)
  • Multiple myeloma is a cancer that starts in plasma cells. (cancer.ca)
  • Multiple myeloma is a serious condition on its own, but both the cancer and the resulting bone damage can lead to several serious long-term effects. (healthline.com)
  • The Malignant Hematology Program at Moffitt Cancer Center is dedicated to the research and treatment of all forms of hematologic cancer, including multiple myeloma. (moffitt.org)
  • Each year, more than 25,000 Americans are diagnosed with multiple myeloma, a form of blood cancer that often develops resistance to therapies. (eurekalert.org)
  • Not only was the combination therapy effective against multiple myeloma cells, it notably did not harm normal bone marrow cells, raising the possibility of therapeutic selectivity," says Grant, the study's lead investigator and Shirley Carter Olsson and Sture Gordon Olsson Chair in Cancer Research, associate director for translational research and program co-leader of Developmental Therapeutics at VCU Massey Cancer Center. (eurekalert.org)
  • Researchers have discovered why multiple myeloma, a difficult to cure cancer of the bone marrow, frequently recurs after an initially effective treatment that can keep the disease at bay for up to several years. (redorbit.com)
  • The research team initially analyzed 7,500 genes in multiple myeloma cells to identify genes which when suppressed made cancer cells resistant to a common class of drugs called proteasome inhibitors such as bortezomib or carfilzomib. (redorbit.com)
  • According to the American Cancer Society, there are three stages of multiple myeloma. (reference.com)
  • The survival rates for multiple myeloma are 62, 44 and 29 months for stages one, two and three, respectively, according to Cancer.org. (reference.com)
  • Multiple myeloma is a form of cancer that is caused by the malignant and abnormal growth of plasma cells. (thirdage.com)
  • The most comprehensive genetic study to date of the blood cancer multiple myeloma has revealed that the genetic landscape of the disease may be more complicated than previously thought. (eurekalert.org)
  • What this new work shows us is that when we treat an individual patient with multiple myeloma, it's possible that we're not just looking at one disease, but at many - in the same person, there could be cancer cells with different genetic make-ups," said co-senior author Todd Golub, the Broad Institute's Chief Scientific Officer and Charles A. Dana Investigator in Human Cancer Genetics at the Dana-Farber Cancer Institute. (eurekalert.org)
  • In a detailed study of samples from more than 200 multiple myeloma patients, Golub and colleagues identified frequent mutations in several key genes known to play an important role in cancer including KRAS, NRAS, and BRAF. (eurekalert.org)
  • In laboratory experiments, multiple myeloma patients had increased levels of sclerostin, which correlated with tumor burden, Homare Eda, MD, PhD, research fellow in cancer at Harvard Medical School in Boston, told MedPage Today . (medpagetoday.com)
  • David Vesole, MD, PhD, co-chief of the myeloma division at John Theurer Cancer Center at Hackensack University Hospital, New Jersey, noted that scientists have been looking for various targets in multiple myeloma and have had success in finding substances in the laboratory that seem like promising targets. (medpagetoday.com)
  • They determined that blood plasma sclerostin levels were higher in the multiple myeloma patients when compared to three leukemia patients, 40 gastric cancer patients, and four healthy volunteers. (medpagetoday.com)
  • Multiple myeloma is a type of cancer that forms in plasma cells (also called mature B-lymphocytes), which are a type of white blood cell that is made in the bone marrow. (drugs.com)
  • If there's one disease that most shows the effects of recent improvements in cancer treatment, it's multiple myeloma. (harvard.edu)
  • The reason, explains research published online today in Cancer Cell , is intrinsic resistance found in immature progenitor cells that are the root cause of the disease - and relapse - says principal investigator Dr. Rodger Tiedemann, a hematologist specializing in multiple myeloma and lymphoma at the Princess Margaret, University Health Network (UHN). (medindia.net)
  • Over time, myeloma recurs and arises because small areas of this cancer may remain undetected and resistant to treatment in the body. (cancer.net)
  • Multiple myeloma is an uncommon cancer. (cancervic.org.au)
  • Multiple myeloma (also known as "myeloma") is the most common primary bone cancer. (aaos.org)
  • Multiple myeloma is named for the "clock face" appearance of the cancer cells when seen under a microscope. (aaos.org)
  • Aflibercept may be able to carry cancer-killing substances directly to multiple myeloma cells. (clinicaltrials.gov)
  • It may also stop the growth of multiple myeloma by blocking blood flow to the cancer. (clinicaltrials.gov)
  • MONTREAL , July 4, 2017 /CNW/ - Multiple myeloma, commonly referred to as myeloma, is an incurable cancer of the plasma cells found in the bone marrow. (newswire.ca)
  • Myeloma Canada is a non-profit, charitable organization created by, and for people living with multiple myeloma, a relatively unknown cancer of the plasma cells. (newswire.ca)
  • Learn more about multiple myeloma or make an appointment at the Winship Cancer Institute of Emory University . (cancerquest.org)
  • The study, a collaborative effort among researchers from Moffitt, Dana-Farber Cancer Institute, Hackensack University Medical Center, Multiple Myeloma Research Consortium, and Celgene Corporation, appeared in the Dec. 14 issue of Blood, the journal of the American Society of Hematology. (innovations-report.com)
  • The novel platform, created by Mount Sinai cancer, genomics, and precision health researchers, expands on traditional DNA-based approaches by using RNA sequencing to find targets for a broad swath of FDA-approved cancer drugs beyond those approved specifically for multiple myeloma. (nursingcenter.com)
  • This approach was tested in a pilot precision medicine clinical trial with 64 patients with late-stage and drug resistant multiple myeloma, the second most common blood cancer. (nursingcenter.com)
  • Our study shows how a precision medicine approach incorporating RNA sequencing may identify viable and effective therapeutic options beyond the current FDA-approved armamentarium for multiple myeloma patients," said researcher Samir Parekh, MD, Associate Professor of Medicine (Hematology and Medical Oncology) and Oncological Sciences and Director of Translational Research in Myeloma at The Tisch Cancer Institute in the Icahn School of Medicine at Mount Sinai. (nursingcenter.com)
  • Research investigators have identified molecular changes in multiple myeloma cells that activate an important biological pathway associated with cell growth and survival, thereby revealing potential new targets for drugs to treat this cancer. (emaxhealth.com)
  • The researchers, led by a team from the National Cancer Institute (NCI), part of the National Institutes of Health, have shown that malignant cells in multiple myeloma frequently harbor mutations that activate what is called the NF-kappaB signaling pathway, which plays a key role in promoting cell growth and preventing programmed cell death. (emaxhealth.com)
  • This is one of the largest collaborative translational cancer research efforts of its kind," said John Shaughnessy, Jr., Ph.D., director of the Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics and chief of Basic Sciences at the Myeloma Institute for Research and Therapy at the University of Arkansas for Medical Sciences, Little Rock, Ark. (emaxhealth.com)
  • Multiple myeloma, a cancer of plasma cells inside the bone marrow, is relatively uncommon but often fatal: About 24,000 people are diagnosed with multiple myeloma in the United States each year. (lifescript.com)
  • As explained in the Introduction , a person with a small amount of M protein in his or her blood has a 1% to 2% chance of developing myeloma, lymphoma , or another blood-related cancer called Waldenstrom's macroglobulinemia per year (see the Stages section for more information). (cancer.net)
  • A clinician who specializes in diseases of the blood, Chapman sees many patients with multiple myeloma - an incurable blood cancer that springs from plasma cells (a type of white blood cell) that have gone awry. (broadinstitute.org)
  • Multiple myeloma is the second most common blood cancer in the United States and causes about 20,000 new cases in this country every year. (broadinstitute.org)
  • These genes, which are frequently mutated, were not on anyone's radar before when thinking about multiple myeloma specifically or cancer in general," said Golub, who is also an investigator at Howard Hughes Medical Institute, and professor of pediatrics at Harvard Medical School. (broadinstitute.org)
Newly diagnosed7
Plasmacytomas3
Lymphoma7
  • Professor Chris Bunce, research director at Leukemia & Lymphoma Research , says this research offers more evidence that the risk of myeloma can be inherited. (medicalnewstoday.com)
  • The LLS mission: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. (lls.org)
  • Multiple myeloma often times originates in the bone marrow and is similar to diseases such as leukemia and lymphoma. (reference.com)
  • a U.S. specialty pharmaceutical company and Clinigen Group plc (AIM: CLIN, 'Clinigen') , the global pharmaceutical and services company, announce a new publication in Leukemia & Lymphoma , with study results showing that amifostine decreases gastro-intestinal (GI) toxicity in patients who receive treatment for their multiple myeloma. (prnewswire.com)
  • Beyond a broad spectrum of related plasma cell disorders that are differentiated based on laboratory and clinical findings, the primary differential considerations for multiple myeloma are metastases and lymphoma/leukemia. (appliedradiology.com)
  • In an interview, Congress Chair Morton Coleman, MD, Director of the Center for Lymphoma and Myeloma at New York-Presbyterian Hospital/Weill Cornell Medical College, agreed: "We are looking for an R-CHOP-like therapy in myeloma. (lww.com)
  • Sequencing multiple tumor genomes] enabled us to pick out which genes are significantly, recurrently mutated in ways that we couldn't have with a single genome," said Chapman, who is supported by a Clinician Scientist Fellowship from Leukaemia and Lymphoma Research. (broadinstitute.org)
Relapse5
Plasma cells28
Cause of multiple myeloma2
  • The cause of multiple myeloma is unclear. (medlineplus.gov)
  • The exact cause of multiple myeloma is not known as of 2015, states Mayo Clinic. (reference.com)
Incidence of multiple myeloma3
  • The incidence of multiple myeloma has been steadily increasing each year. (nurse.com)
  • Occupational exposure - The incidence of multiple myeloma tends to be higher than average among people in certain occupations, including agricultural and farm workers, cosmetologists, petroleum workers and employees in the leather industry. (moffitt.org)
  • There is an increased incidence of multiple myeloma in persons with rheumatoid arthritis or obesity (body mass index of more than 30 kg per m 2 ). (aafp.org)
Individuals with multiple myeloma1
  • These chromosome abnormalities may be an explanation for the wide variation in response to treatment among individuals with multiple myeloma. (healthcentral.com)
Disease33
Incurable3
Develop multiple myeloma3
  • In Western industrialized countries, approximately four people in 100,000 develop multiple myeloma. (encyclopedia.com)
  • Black people are about twice as likely to develop multiple myeloma as are white people. (mayoclinic.org)
  • African Americans are more than twice as likely to develop multiple myeloma than white Americans. (thirdage.com)
People with myeloma5
  • Only 20% of people with myeloma have this kind. (webmd.com)
  • This rare type affects only 1% to 2% of all people with myeloma. (webmd.com)
  • Age is a risk factor for myeloma, with 96 percent of people with myeloma aged over 45 years. (medicalnewstoday.com)
  • Our specialists monitor people with myeloma who are being cared for at home in collaboration with local infusion companies, visiting nurses, and hospice workers. (mskcc.org)
  • They are often prescribed to control pain in people with myeloma. (mskcc.org)
Levels in multiple myeloma patients2
  • These data demonstrate that increased sclerostin levels in multiple myeloma patients inhibit osteoblastogenesis and stimulate osteoclastogenesis," he suggested. (medpagetoday.com)
  • NEW YORK (GenomeWeb) - Researchers from Erasmus MC University Medical Center and Radboud University Medical Center in The Netherlands have developed a mass spec-based test for measuring M protein levels in multiple myeloma patients. (genomeweb.com)
Symptoms of multiple myeloma include1
Effectively kill multiple myeloma cells1
  • Anti-nausea drug thalidomide when combined with turmeric can effectively kill multiple myeloma cells, say researchers. (medindia.net)
Patients with relapsed refractory multiple myeloma1
Cells43
Pathogenesis3
  • Here we review the current understanding of myeloma pathogenesis and insight into new therapeutic strategies provided by animal models and genetic screens. (jci.org)
  • 1,2 The exact pathogenesis of multiple myeloma is unknown, but there is increased incidence in males and African Americans as well as with exposure to various environmental factors. (appliedradiology.com)
  • The aberrant role of miRNAs has been reported in a number of hematopoietic malignancies including multiple myeloma (MM). In this review we summarize the current knowledge on roles of miRNAs in the pathogenesis of MM. (frontiersin.org)
Bone marrow2
Anti-myeloma1
  • The study concluded that amifostine therapy decreased GI toxicity without any significant adverse effects while preserving the anti-myeloma efficacy of high-dose melphalan and auto-HTC. (prnewswire.com)
Refractory myeloma2
Relapsed and refractory multiple myeloma1
Risk factors for multiple myeloma1
Treatment regimens for multiple myeloma1
  • Noopur Raje, MD, assistant professor of medicine and director of the Center for Multiple Myeloma at Massachusetts General Hospital/Harvard Medical School said, however, that cost was often not a major factor in selection of treatment regimens for multiple myeloma. (medpagetoday.com)
Advanced multiple myeloma based1
  • Kyprolis, acquired by Amgen in its $10 billion takeover of Onyx Pharmaceuticals, was approved in the United States for treating advanced multiple myeloma based on data showing that patients responded to the drug. (yahoo.com)
Assessed multiple myeloma patients1
Leukemia3
Therapy6
  • The Total Therapy treatment regimens developed at the Myeloma Institute have demonstrated great improvement in treatment outcomes for multiple myeloma patients. (clinicaltrials.gov)
  • Nongenetic factors that increase the risk of developing multiple myeloma include previous radiation therapy or other radiation exposure. (medlineplus.gov)
  • Today we approved a treatment under our accelerated approval program that provides a treatment option for patients with multiple myeloma with no available therapy. (fda.gov)
  • On the basis of these results, the company has submitted an approval application to the US Food and Drug Administration for use of belantamab mafodotin in the treatment of patients with relapsed or refractory multiple myeloma whose prior therapy includes an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody. (medscape.com)
  • [ 9 ] MRI is the gold-standard imaging modality for detection of bone marrow involvement and the preferred imaging technique to rule out spinal cord compression in patients with multiple myeloma, whereas PET/CT provides valuable prognostic data and aids in assessment of response to therapy. (medscape.com)
  • The new findings will not immediately change the treatment options for Chapman's patients - although there is a glimmer of promise for some that could result in a new, more effective therapy - but the results are already impacting the future of multiple myeloma research. (broadinstitute.org)
Blood13
What is multiple myeloma? - Canadian Cancer Society
What is multiple myeloma? - Canadian Cancer Society (cancer.ca)
Multiple Myeloma Awareness T-Shirt | Spreadshirt
Multiple Myeloma Awareness T-Shirt | Spreadshirt (spreadshirt.com)
Multiple Myeloma Diagnosis, Causes, Definition, Symptoms, Stages
Multiple Myeloma Diagnosis, Causes, Definition, Symptoms, Stages (emedicinehealth.com)
What is multiple myeloma? (video) | Khan Academy
What is multiple myeloma? (video) | Khan Academy (khanacademy.org)
Multiple Myeloma Research in Progress at The James
Multiple Myeloma Research in Progress at The James (cancer.osu.edu)
Bone Marrow Stromal Cells Derived MCP-1 Reverses the Inhibitory Effects of Multiple Myeloma Cells on Osteoclastogenesis by...
Bone Marrow Stromal Cells Derived MCP-1 Reverses the Inhibitory Effects of Multiple Myeloma Cells on Osteoclastogenesis by... (journals.plos.org)
Multiple Myeloma, Schmorl's Nodes, Tremor: Causes & Reasons - Symptoma®
Multiple Myeloma, Schmorl's Nodes, Tremor: Causes & Reasons - Symptoma® (symptoma.com)
Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper...
Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper... (nature.com)
BRAF gene: MedlinePlus Genetics
BRAF gene: MedlinePlus Genetics (medlineplus.gov)
Bone marrow cancer: Symptoms, treatment, and outlook
Bone marrow cancer: Symptoms, treatment, and outlook (medicalnewstoday.com)
MedPix Case - Multiple myeloma
MedPix Case - Multiple myeloma (medpix.nlm.nih.gov)
Leukemia
Leukemia (nature.com)
Cancer Types - Moon Shots Program | MD Anderson Cancer Center
Cancer Types - Moon Shots Program | MD Anderson Cancer Center (mdanderson.org)
Doxil - FDA prescribing information, side effects and uses
Doxil - FDA prescribing information, side effects and uses (drugs.com)
Educational, Cancer, Workshops | CancerCare
Educational, Cancer, Workshops | CancerCare (cancercare.org)
Blood cancer symptoms and signs: Look out for nosebleeds and bleeding gums | Express.co.uk
Blood cancer symptoms and signs: Look out for nosebleeds and bleeding gums | Express.co.uk (express.co.uk)
Thalomid (Thalidomide): Uses, Dosage, Side Effects, Interactions, Warning
Thalomid (Thalidomide): Uses, Dosage, Side Effects, Interactions, Warning (rxlist.com)
Multiple Myeloma: Clinical Update | Memorial Sloan Kettering Cancer Center
Multiple Myeloma: Clinical Update | Memorial Sloan Kettering Cancer Center (mskcc.org)
Multiple Myeloma | Novartis
Multiple Myeloma | Novartis (novartis.com)
How to Diagnose Multiple Myeloma (with Pictures) - wikiHow
How to Diagnose Multiple Myeloma (with Pictures) - wikiHow (wikihow.com)
Multiple Myeloma Imaging: Practice Essentials, Radiography, Computed Tomography
Multiple Myeloma Imaging: Practice Essentials, Radiography, Computed Tomography (emedicine.medscape.com)
Multiple Myeloma Symptoms
Multiple Myeloma Symptoms (news-medical.net)
Save Life Amyloidosis Trough Multiple Myeloma by Maurice Vahedifar, D.M.D., M.S. (Paperback) - Lulu
Save Life Amyloidosis Trough Multiple Myeloma by Maurice Vahedifar, D.M.D., M.S. (Paperback) - Lulu (lulu.com)
5 Biotech Stocks That Could Be Bought Out in 2018 | Fox Business
5 Biotech Stocks That Could Be Bought Out in 2018 | Fox Business (foxbusiness.com)
Multiple myeloma: Symptoms, causes, and treatment
Multiple myeloma: Symptoms, causes, and treatment (medicalnewstoday.com)
What is Multiple Myeloma?
What is Multiple Myeloma? (news-medical.net)
Stem Cell Transplants: How Do They Work? | HealthCentral
Stem Cell Transplants: How Do They Work? | HealthCentral (healthcentral.com)
Questions & Answers
Questions & Answers (emedicine.medscape.com)
Multiple Myeloma Differential Diagnoses
Multiple Myeloma Differential Diagnoses (emedicine.medscape.com)
Sinomenine derivative YL064: a novel STAT3 inhibitor with promising anti-myeloma activity | Cell Death & Disease
Sinomenine derivative YL064: a novel STAT3 inhibitor with promising anti-myeloma activity | Cell Death & Disease (nature.com)
Lab Designed Bone Marrow Implant Makes Marrow Transplant Safer
Lab Designed Bone Marrow Implant Makes Marrow Transplant Safer (medindia.net)